

Christie M Ballantyne

List of Publications by Year in Descending Order

Source: <https://exaly.com/author-pdf/5473952/christie-m-ballantyne-publications-by-year.pdf>

Version: 2024-04-19

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

884
papers

66,855
citations

121
h-index

235
g-index

1,095
ext. papers

78,980
ext. citations

7.6
avg, IF

7.62
L-index

#	Paper	IF	Citations
884	NT-pro B-type natriuretic peptide, early menopause, and incident heart failure in postmenopausal women of the ARIC study.. <i>Menopause</i> , 2022 , 29, 309-316	2.5	1
883	Consistency of Benefit of Icosapent Ethyl by Background Statin Type in REDUCE-IT.. <i>Journal of the American College of Cardiology</i> , 2022 , 79, 220-222	15.1	2
882	Utilization Rates of SGLT2 Inhibitors and GLP-1 Receptor Agonists and Their Facility-Level Variation Among Patients With Atherosclerotic Cardiovascular Disease and Type 2 Diabetes: Insights From the Department of Veterans Affairs.. <i>Diabetes Care</i> , 2022 ,	14.6	6
881	Increased prevalence of clonal hematopoiesis of indeterminate potential amongst people living with HIV.. <i>Scientific Reports</i> , 2022 , 12, 577	4.9	3
880	Heart Failure Risk Associated With Severity of Modifiable Heart Failure Risk Factors: The ARIC Study.. <i>Journal of the American Heart Association</i> , 2022 , 11, e021583	6	2
879	Apolipoprotein C-III reduction in subjects with moderate hypertriglyceridaemia and at high cardiovascular risk.. <i>European Heart Journal</i> , 2022 ,	9.5	8
878	Leveraging structured and unstructured electronic health record data to detect reasons for suboptimal statin therapy use in patients with atherosclerotic cardiovascular disease.. <i>American Journal of Preventive Cardiology</i> , 2022 , 9, 100300	1.9	0
877	Cost-effectiveness of Icosapent Ethyl for High-risk Patients With Hypertriglyceridemia Despite Statin Treatment.. <i>JAMA Network Open</i> , 2022 , 5, e2148172	10.4	1
876	Treatment With Icosapent Ethyl to Reduce Ischemic Events in Patients With Prior Percutaneous Coronary Intervention: Insights From REDUCE-IT PCI.. <i>Journal of the American Heart Association</i> , 2022 , e022937	6	3
875	Diabetes, GDF-15 and incident heart failure: the atherosclerosis risk in communities study.. <i>Diabetologia</i> , 2022 , 1	10.3	1
874	Associations of High-Sensitivity Troponin and Natriuretic Peptide Levels With Serious Adverse Events in SPRINT.. <i>Journal of the American Heart Association</i> , 2022 , e023314	6	
873	A Head-to-Head Comparison of a Free Fatty Acid Formulation of Omega-3 Pentaenoic Acids Versus Icosapent Ethyl in Adults With Hypertriglyceridemia: The ENHANCE-IT Study.. <i>Journal of the American Heart Association</i> , 2022 , e024176	6	0
872	Impact of Icosapent Ethyl on Cardiovascular Risk Reduction in Patients With Heart Failure in REDUCE-IT.. <i>Journal of the American Heart Association</i> , 2022 , 11, e024999	6	0
871	Mendelian randomization supports bidirectional causality between telomere length and clonal hematopoiesis of indeterminate potential.. <i>Science Advances</i> , 2022 , 8, eabl6579	14.3	3
870	A proteomic surrogate for cardiovascular outcomes that is sensitive to multiple mechanisms of change in risk.. <i>Science Translational Medicine</i> , 2022 , 14, eabj9625	17.5	3
869	Obesity, Galectin-3, and Incident Heart Failure: The ARIC Study.. <i>Journal of the American Heart Association</i> , 2022 , 11, e023238	6	0
868	Prevention of Cardiovascular Events and Mortality With Icosapent Ethyl in Patients With Prior Myocardial Infarction.. <i>Journal of the American College of Cardiology</i> , 2022 , 79, 1660-1671	15.1	7

867	Midlife determinants of healthy cardiovascular aging: The Atherosclerosis Risk in Communities (ARIC) study.. <i>Atherosclerosis</i> , 2022 , 350, 82-89	3.1	0
866	Cardiac Structure and Function Across the Spectrum of Aldosteronism: the Atherosclerosis Risk in Communities Study.. <i>Hypertension</i> , 2022 , 101161HYPERTENSIONAHA12219134	8.5	0
865	Hypercholesterolemia. <i>Contemporary Cardiology</i> , 2022 , 61-71	0.1	
864	Existing and emerging strategies to lower Lipoprotein(a). <i>Atherosclerosis</i> , 2022 , 349, 110-122	3.1	9
863	Lipoprotein(a) and ethnicities. <i>Atherosclerosis</i> , 2022 , 349, 42-52	3.1	5
862	Poloxamer 407 Induces Hypertriglyceridemia but Decreases Atherosclerosis in Ldlr ^{-/-} Mice. <i>Cells</i> , 2022 , 11, 1795	7.9	
861	JCL Roundtable. Making prevention a priority. <i>Journal of Clinical Lipidology</i> , 2021 , 15, 530-537	4.9	1
860	Determinants of Incident Atherosclerotic Cardiovascular Disease Events Among Those With Absent Coronary Artery Calcium: Multi-Ethnic Study of Atherosclerosis. <i>Circulation</i> , 2021 ,	16.7	4
859	DCRM Multispecialty Practice Recommendations for the management of diabetes, cardiorenal, and metabolic diseases.. <i>Journal of Diabetes and Its Complications</i> , 2021 , 36, 108101	3.2	2
858	Identification of Functional Genetic Determinants of Cardiac Troponin T and I in a Multiethnic Population and Causal Associations With Atrial Fibrillation. <i>Circulation Genomic and Precision Medicine</i> , 2021 , CIRCGEN121003460	5.2	0
857	Clonal Hematopoiesis Is Associated With Higher Risk of Stroke. <i>Stroke</i> , 2021 , STROKEAHA121037388	6.7	7
856	The Fifth-Generation Cardiac Troponin T and Cardiovascular Disease in the Community. <i>Journal of the American College of Cardiology</i> , 2021 , 78, 2019-2021	15.1	
855	Proteomics and Risk of Atrial Fibrillation in Older Adults (From the Atherosclerosis Risk in Communities [ARIC] Study). <i>American Journal of Cardiology</i> , 2021 , 161, 42-50	3	0
854	Comparative Reductions in Investigator-Reported and Adjudicated Ischemic Events in REDUCE-IT. <i>Journal of the American College of Cardiology</i> , 2021 , 78, 1525-1537	15.1	6
853	PCSK9-targeted therapies: present and future approaches. <i>Nature Reviews Cardiology</i> , 2021 , 18, 805-806	14.8	2
852	Effect of bempedoic acid plus ezetimibe fixed-dose combination vs ezetimibe or placebo on low-density lipoprotein cholesterol in patients with type 2 diabetes and hypercholesterolemia not treated with statins. <i>American Journal of Preventive Cardiology</i> , 2021 , 8, 100278	1.9	2
851	Icosapent Ethyl Reduces Ischemic Events in Patients With a History of Previous Coronary Artery Bypass Grafting: REDUCE-IT CABG. <i>Circulation</i> , 2021 , 144, 1845-1855	16.7	10
850	Benefits of Icosapent Ethyl Across the Range of Kidney Function in Patients With Established Cardiovascular Disease or Diabetes: REDUCE-IT RENAL. <i>Circulation</i> , 2021 , 144, 1750-1759	16.7	8

849	Transatlantic guidelines on dyslipidemia and cardiovascular risk: key differences across the pond. <i>Current Opinion in Endocrinology, Diabetes and Obesity</i> , 2021 , 28, 114-121	4	
848	Lipid-Lowering Biotechnological Drugs: from Monoclonal Antibodies to Antisense Therapies-a Clinical Perspective. <i>Cardiovascular Drugs and Therapy</i> , 2021 , 35, 1269-1279	3.9	7
847	High-Sensitivity Cardiac Troponin, Natriuretic Peptide, and Long-Term Risk of Acute Kidney Injury: The Atherosclerosis Risk in Communities (ARIC) Study. <i>Clinical Chemistry</i> , 2021 , 67, 298-307	5.5	2
846	Associations Between Carotid Artery Plaque Burden, Plaque Characteristics, and Cardiovascular Events: The ARIC Carotid Magnetic Resonance Imaging Study. <i>JAMA Cardiology</i> , 2021 , 6, 79-86	16.2	6
845	Conventional and Novel Lipid Measures and Risk of Peripheral Artery Disease. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2021 , 41, 1229-1238	9.4	9
844	Genetically determined NLRP3 inflammasome activation associates with systemic inflammation and cardiovascular mortality. <i>European Heart Journal</i> , 2021 , 42, 1742-1756	9.5	20
843	Ten things to know about ten cardiovascular disease risk factors. <i>American Journal of Preventive Cardiology</i> , 2021 , 5, 100149	1.9	19
842	Loss of bone morphogenetic protein-binding endothelial regulator causes insulin resistance. <i>Nature Communications</i> , 2021 , 12, 1927	17.4	5
841	Racial and geographic disparities in influenza vaccination in the U.S. among individuals with atherosclerotic cardiovascular disease: Renewed importance in the setting of COVID-19. <i>American Journal of Preventive Cardiology</i> , 2021 , 5, 100150	1.9	4
840	Biomarker-Based Risk Prediction of Incident Heart Failure in Pre-Diabetes and Diabetes. <i>JACC: Heart Failure</i> , 2021 , 9, 215-223	7.9	12
839	How Do We Incorporate Polygenic Risk Scores in Cardiovascular Disease Risk Assessment and Management?. <i>Current Atherosclerosis Reports</i> , 2021 , 23, 28	6	3
838	Chromosome Xq23 is associated with lower atherogenic lipid concentrations and favorable cardiometabolic indices. <i>Nature Communications</i> , 2021 , 12, 2182	17.4	5
837	Role of Bempedoic Acid in Clinical Practice. <i>Cardiovascular Drugs and Therapy</i> , 2021 , 35, 853-864	3.9	16
836	Soluble Angiotensin-Converting Enzyme 2, Cardiac Biomarkers, Structure, and Function, and Cardiovascular Events (from the Atherosclerosis Risk in Communities Study). <i>American Journal of Cardiology</i> , 2021 , 146, 15-21	3	5
835	Health care costs associated with primary care physicians versus nurse practitioners and physician assistants. <i>Journal of the American Association of Nurse Practitioners</i> , 2021 , 33, 967-974	1	
834	High Burden of Subclinical and Cardiovascular Disease Risk in Adults With Metabolically Healthy Obesity: The Atherosclerosis Risk in Communities (ARIC) Study. <i>Diabetes Care</i> , 2021 , 44, 1657-1663	14.6	3
833	Efficacy and safety of volanesorsen in patients with multifactorial chylomicronaemia (COMPASS): a multicentre, double-blind, randomised, placebo-controlled, phase 3 trial. <i>Lancet Diabetes and Endocrinology</i> , 2021 , 9, 264-275	18.1	28
832	Association Between Omega-3 Fatty Acid Treatment and Atrial Fibrillation in Cardiovascular Outcome Trials: A Systematic Review and Meta-Analysis. <i>Cardiovascular Drugs and Therapy</i> , 2021 , 35, 793-800	3.9	2

831	Large-scale plasma proteomic analysis identifies proteins and pathways associated with dementia risk. <i>Nature Aging</i> , 2021 , 1, 473-489		6
830	CD11c participates in triggering acute graft-versus-host disease during bone marrow transplantation. <i>Immunology</i> , 2021 , 164, 148-160	7.8	1
829	Six-year changes in N-terminal pro-brain natriuretic peptide and changes in weight and risk of obesity. <i>Obesity</i> , 2021 , 29, 1215-1222	8	
828	Social Determinants of Health and Comorbidities Among Individuals with Atherosclerotic Cardiovascular Disease: The Behavioral Risk Factor Surveillance System Survey. <i>Population Health Management</i> , 2021 ,	1.8	2
827	The ARIC (Atherosclerosis Risk In Communities) Study: JACC Focus Seminar 3/8. <i>Journal of the American College of Cardiology</i> , 2021 , 77, 2939-2959	15.1	23
826	Development and Validation of Machine Learning-Based Race-Specific Models to Predict 10-Year Risk of Heart Failure: A Multicohort Analysis. <i>Circulation</i> , 2021 , 143, 2370-2383	16.7	13
825	Sex-Related Disparities in Cardiovascular Health Care Among Patients With Premature Atherosclerotic Cardiovascular Disease. <i>JAMA Cardiology</i> , 2021 , 6, 782-790	16.2	6
824	Upper Reference Limits for High-Sensitivity Cardiac Troponin T and N-Terminal Fragment of the Prohormone Brain Natriuretic Peptide in Patients With CKD. <i>American Journal of Kidney Diseases</i> , 2021 ,	7.4	1
823	Greater than expected reduction in low-density lipoprotein-cholesterol (LDL-C) with bempedoic acid in a patient with heterozygous familial hypercholesterolemia (HeFH). <i>Journal of Clinical Lipidology</i> , 2021 ,	4.9	3
822	Mid- to Late-Life Inflammation and Risk of Cardiac Dysfunction, HFpEF and HFrEF in Late Life. <i>Journal of Cardiac Failure</i> , 2021 , 27, 1382-1392	3.3	0
821	Relation of Magnetic Resonance Imaging Based Arterial Signal Enhancement to Markers of Peripheral Artery Disease. <i>American Journal of Cardiology</i> , 2021 , 140, 140-147	3	1
820	Reduction in Revascularization With Icosapent Ethyl: Insights From REDUCE-IT Revascularization Analyses. <i>Circulation</i> , 2021 , 143, 33-44	16.7	25
819	High-Sensitivity Cardiac Troponin I for Risk Stratification in Older Adults. <i>Journal of the American Geriatrics Society</i> , 2021 , 69, 986-994	5.6	1
818	Association of Circulating Monocyte Chemoattractant Protein-1 Levels With Cardiovascular Mortality: A Meta-analysis of Population-Based Studies. <i>JAMA Cardiology</i> , 2021 , 6, 587-592	16.2	8
817	REDUCE-IT INTERIM: accumulation of data across prespecified interim analyses to final results. <i>European Heart Journal - Cardiovascular Pharmacotherapy</i> , 2021 , 7, e61-e63	6.4	9
816	New Approaches for the Prevention and Treatment of Cardiovascular Disease: Focus on Lipoproteins and Inflammation. <i>Annual Review of Medicine</i> , 2021 , 72, 431-446	17.4	5
815	Residual Cardiovascular Risk at Low LDL: Remnants, Lipoprotein(a), and Inflammation. <i>Clinical Chemistry</i> , 2021 , 67, 143-153	5.5	23
814	Association of NT-ProBNP, Blood Pressure, and Cardiovascular Events: The ARIC Study. <i>Journal of the American College of Cardiology</i> , 2021 , 77, 559-571	15.1	5

813	Deficiency of Stat1 in CD11c Cells Alters Adipose Tissue Inflammation and Improves Metabolic Dysfunctions in Mice Fed a High-Fat Diet. <i>Diabetes</i> , 2021 , 70, 720-732	0.9	4
812	Racial and Geographic Disparities in Internet Use in the U.S. Among Patients With Hypertension or Diabetes: Implications for Telehealth in the Era of COVID-19. <i>Diabetes Care</i> , 2021 , 44, e15-e17	14.6	16
811	Temporal Trends in E-Cigarette and Cigarette Use Among US Adults by US State: Behavioral Risk Factor Surveillance System, 2016 to 2018. <i>Population Health Management</i> , 2021 , 24, 414-415	1.8	0
810	Eligibility for Low-Dose Rivaroxaban Based on the COMPASS Trial: Insights from the Veterans Affairs Healthcare System. <i>Cardiovascular Drugs and Therapy</i> , 2021 , 35, 533-538	3.9	
809	Significant Facility-Level Variation in Utilization of and Adherence with Secondary Prevention Therapies Among Patients with Premature Atherosclerotic Cardiovascular Disease: Insights from the VITAL (Veterans with preMaTure Atherosclerosis) Registry7. <i>Cardiovascular Drugs and Therapy</i> , 2021 , 1	3.9	2
808	Triglyceride-rich lipoproteins, apolipoprotein C-III, angiotensin-like protein 3, and cardiovascular events in older adults: Atherosclerosis Risk in Communities (ARIC) study. <i>European Journal of Preventive Cardiology</i> , 2021 ,	3.9	6
807	Genome-wide association study of circulating interleukin 6 levels identifies novel loci. <i>Human Molecular Genetics</i> , 2021 , 30, 393-409	5.6	6
806	Recreational substance use among patients with premature atherosclerotic cardiovascular disease. <i>Heart</i> , 2021 , 107, 650-656	5.1	8
805	Facility-Level Variation in Reported Statin-Associated Side Effects Among Patients with Atherosclerotic Cardiovascular Disease-Perspective from the Veterans Affairs Healthcare System. <i>Cardiovascular Drugs and Therapy</i> , 2021 , 1	3.9	4
804	Growth Differentiation Factor (GDF)-15 and Cardiometabolic Outcomes among Older Adults: The Atherosclerosis Risk in Communities Study. <i>Clinical Chemistry</i> , 2021 , 67, 653-661	5.5	6
803	Has the 'strength' of fish oil therapy been 'reduced'? Reconciling the results of REDUCE-IT and STRENGTH. <i>European Heart Journal - Cardiovascular Pharmacotherapy</i> , 2021 , 7, e7-e8	6.4	3
802	Supplemental Association of Clonal Hematopoiesis With Incident Heart Failure. <i>Journal of the American College of Cardiology</i> , 2021 , 78, 42-52	15.1	16
801	Lipid Monitoring After Initiation of Lipid-Lowering Therapies: Return of Performance Measures?. <i>Current Cardiology Reports</i> , 2021 , 23, 116	4.2	1
800	Association of Longitudinal Changes in Cardiac Biomarkers With Atrial and Ventricular Arrhythmias (from the Atherosclerosis Risk in Communities [ARIC] Study). <i>American Journal of Cardiology</i> , 2021 , 158, 45-52	3	0
799	Association Between Achieved Ω 3 Fatty Acid Levels and Major Adverse Cardiovascular Outcomes in Patients With High Cardiovascular Risk: A Secondary Analysis of the STRENGTH Trial. <i>JAMA Cardiology</i> , 2021 ,	16.2	13
798	Proteins Associated with Risk of Kidney Function Decline in the General Population. <i>Journal of the American Society of Nephrology: JASN</i> , 2021 , 32, 2291-2302	12.7	2
797	Premature Atherosclerotic Cardiovascular Disease Risk Among Patients with Inflammatory Bowel Disease. <i>American Journal of Medicine</i> , 2021 , 134, 1047-1051.e2	2.4	3
796	Association between circulating Galectin-3 and arterial stiffness in older adults. <i>Vasa - European Journal of Vascular Medicine</i> , 2021 , 50, 439-445	1.9	

795	Genetic testing in ambulatory cardiology clinics reveals high rate of findings with clinical management implications. <i>Genetics in Medicine</i> , 2021 , 23, 2404-2414	8.1	3
794	What Do US Physicians and Patients Think About Lipid-Lowering Therapy and Goals of Treatment? Results From the GOULD Registry. <i>Journal of the American Heart Association</i> , 2021 , 10, e020893	6	0
793	Effect of omega-3 fatty acids on cardiovascular outcomes: A systematic review and meta-analysis. <i>EClinicalMedicine</i> , 2021 , 38, 100997	11.3	21
792	2021 ACC Expert Consensus Decision Pathway on the Management of ASCVD Risk Reduction in Patients With Persistent Hypertriglyceridemia: A Report of the American College of Cardiology Solution Set Oversight Committee. <i>Journal of the American College of Cardiology</i> , 2021 , 78, 960-993	15.1	28
791	Use of Lipid-Lowering Therapies Over 2 Years in GOULD, a Registry of Patients With Atherosclerotic Cardiovascular Disease in the US. <i>JAMA Cardiology</i> , 2021 ,	16.2	12
790	Associations of High-Sensitivity Troponin and Natriuretic Peptide Levels With Outcomes After Intensive Blood Pressure Lowering: Findings From the SPRINT Randomized Clinical Trial. <i>JAMA Cardiology</i> , 2021 ,	16.2	1
789	Technology-Assisted Self-Selection of Candidates for Nonprescription Statin Therapy. <i>Journal of the American College of Cardiology</i> , 2021 , 78, 1114-1123	15.1	3
788	Racial Disparities in Modifiable Risk Factors and Statin Usage in Black Patients With Familial Hypercholesterolemia. <i>Journal of the American Heart Association</i> , 2021 , 10, e020890	6	0
787	Cardiovascular Disease Risk-Based Statin Utilization and Associated Outcomes in a Primary Prevention Cohort: Insights From a Large Health Care Network. <i>Circulation: Cardiovascular Quality and Outcomes</i> , 2021 , 14, e007485	5.8	1
786	Endothelium-specific depletion of LRP1 improves glucose homeostasis through inducing osteocalcin. <i>Nature Communications</i> , 2021 , 12, 5296	17.4	1
785	Lipid measurements in the management of cardiovascular diseases: Practical recommendations a scientific statement from the national lipid association writing group. <i>Journal of Clinical Lipidology</i> , 2021 ,	4.9	6
784	Prevalence and Determinants of Difficulty in Accessing Medical Care in U.S. Adults. <i>American Journal of Preventive Medicine</i> , 2021 , 61, 492-500	6.1	2
783	High-sensitivity cardiac troponin T and the risk of heart failure in postmenopausal women of the ARIC Study. <i>Menopause</i> , 2021 , 28, 284-291	2.5	3
782	C-reactive protein levels and plaque regression with evolocumab: Insights from GLAGOV. <i>American Journal of Preventive Cardiology</i> , 2020 , 3, 100091	1.9	0
781	Large-scale plasma proteomic analysis identifies proteins and biological pathways associated with incident dementia. <i>Alzheimer's and Dementia</i> , 2020 , 16, e038307	1.2	1
780	Age-Stratified Sex Disparities in Care and Outcomes in Patients With ST-Elevation Myocardial Infarction. <i>American Journal of Medicine</i> , 2020 , 133, 1293-1301.e1	2.4	14
779	Androgens In Men Study (AIMS): protocol for meta-analyses of individual participant data investigating associations of androgens with health outcomes in men. <i>BMJ Open</i> , 2020 , 10, e034777	3	1
778	Physical Activity and Incident Heart Failure in High-Risk Subgroups: The ARIC Study. <i>Journal of the American Heart Association</i> , 2020 , 9, e014885	6	6

777	Metabolic Inflammation and Insulin Resistance in Obesity. <i>Circulation Research</i> , 2020 , 126, 1549-1564	15.7	127
776	Associations of 1,5-Anhydroglucitol and 2-Hour Glucose with Major Clinical Outcomes in the Atherosclerosis Risk in Communities (ARIC) Study. <i>Journal of applied laboratory medicine, The</i> , 2020 , 5, 1296-1306	2	1
775	Triglycerides and ASCVD Risk Reduction: Recent Insights and Future Directions. <i>Current Atherosclerosis Reports</i> , 2020 , 22, 25	6	17
774	Associations Between High-Density Lipoprotein Particles and Ischemic Events by Vascular Domain, Sex, and Ethnicity: A Pooled Cohort Analysis. <i>Circulation</i> , 2020 , 142, 657-669	16.7	19
773	JCL roundtable: Omega-3 fatty acids and cardiovascular outcomes. <i>Journal of Clinical Lipidology</i> , 2020 , 14, 4-15	4.9	3
772	Performance of High-Sensitivity Cardiac Troponin Assays to Reflect Comorbidity Burden and Improve Mortality Risk Stratification in Older Adults With Diabetes. <i>Diabetes Care</i> , 2020 , 43, 1200-1208	14.6	17
771	Cardiac Biomarkers and Subsequent Risk of Hospitalization With Bleeding in the Community: Atherosclerosis Risk in Communities Study. <i>Journal of the American Heart Association</i> , 2020 , 9, e013560	6	4
770	Levels and Change in Galectin-3 and Association With Cardiovascular Events: The ARIC Study. <i>Journal of the American Heart Association</i> , 2020 , 9, e015405	6	7
769	Acute Tubular Injury in a Patient on a Proprotein Convertase Subtilisin/Kexin Type 9 Inhibitor. <i>JACC: Case Reports</i> , 2020 , 2, 1042-1045	1.2	1
768	Autoimmune Rheumatic Diseases and Premature Atherosclerotic Cardiovascular Disease: An Analysis From the VITAL Registry. <i>American Journal of Medicine</i> , 2020 , 133, 1424-1432.e1	2.4	10
767	Facility-Level Variation in Cardiac Stress Test Use Among Patients With Diabetes: Findings From the Veterans Affairs National Database. <i>Diabetes Care</i> , 2020 , 43, e58-e60	14.6	3
766	The Use of Sex-Specific Factors in the Assessment of Women's Cardiovascular Risk. <i>Circulation</i> , 2020 , 141, 592-599	16.7	45
765	Racial Differences in Malignant Left Ventricular Hypertrophy and Incidence of Heart Failure: A Multicohort Study. <i>Circulation</i> , 2020 , 141, 957-967	16.7	15
764	Association of Isolated Diastolic Hypertension as Defined by the 2017 ACC/AHA Blood Pressure Guideline With Incident Cardiovascular Outcomes. <i>JAMA - Journal of the American Medical Association</i> , 2020 , 323, 329-338	27.4	57
763	Impact of Lipid Monitoring on Treatment Intensification of Cholesterol Lowering Therapies (from the Veterans Affairs Healthcare System). <i>American Journal of Cardiology</i> , 2020 , 125, 874-879	3	5
762	Dalcetrapib Reduces Risk of New-Onset Diabetes in Patients With Coronary Heart Disease. <i>Diabetes Care</i> , 2020 , 43, 1077-1084	14.6	13
761	Real-world data, theoretical application of guidelines, cost, and access: how do we optimize non-statin therapy for LDL-C/non-HDL-C/ApoB?. <i>European Heart Journal</i> , 2020 , 41, 3910-3912	9.5	4
760	Associations of Cardiac, Kidney, and Diabetes Biomarkers With Peripheral Neuropathy among Older Adults in the Atherosclerosis Risk in Communities (ARIC) Study. <i>Clinical Chemistry</i> , 2020 , 66, 686-695	5.5	5

759	E-cigarette Use and Risk Behaviors among Lesbian, Gay, Bisexual, and Transgender Adults: The Behavioral Risk Factor Surveillance System (BRFSS) Survey. <i>Kansas Journal of Medicine</i> , 2020 , 13, 318-321	0.6	6
758	PRECISION MEDICINE FOR CARDIOVASCULAR DISEASE PREVENTION: WHERE DO WE STAND IN 2019 WITH A FOCUS ON INFLAMMATION AND LIPIDS?. <i>Transactions of the American Clinical and Climatological Association</i> , 2020 , 131, 42-47	0.9	
757	Coronary artery disease in the young in the US population-based cohort. <i>American Journal of Cardiovascular Disease</i> , 2020 , 10, 189-194	0.9	5
756	Cardiovascular risk and complications associated with COVID-19. <i>American Journal of Cardiovascular Disease</i> , 2020 , 10, 479-489	0.9	7
755	Increased CHIP Prevalence Amongst People Living with HIV 2020 ,		5
754	Dietary and Pharmacological Fatty Acids and Cardiovascular Health. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2020 , 105,	5.6	11
753	REDUCE-IT USA: Results From the 3146 Patients Randomized in the United States. <i>Circulation</i> , 2020 , 141, 367-375	16.7	67
752	Getting to an ImprOved Understanding of Low-Density Lipoprotein-Cholesterol and Dyslipidemia Management (GOULD): Methods and baseline data of a registry of high cardiovascular risk patients in the United States. <i>American Heart Journal</i> , 2020 , 219, 70-77	4.9	9
751	Association of high-density lipoprotein particle concentration with cardiovascular risk following acute coronary syndrome: A case-cohort analysis of the dal-Outcomes trial. <i>American Heart Journal</i> , 2020 , 221, 60-66	4.9	3
750	Mortality Implications of Prediabetes and Diabetes in Older Adults. <i>Diabetes Care</i> , 2020 , 43, 382-388	14.6	23
749	Plasma Dehydroepiandrosterone Sulfate and Cardiovascular Disease Risk in Older Men and Women. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2020 , 105,	5.6	9
748	Bempedoic acid safety analysis: Pooled data from four phase 3 clinical trials. <i>Journal of Clinical Lipidology</i> , 2020 , 14, 649-659.e6	4.9	24
747	Monocyte phenotyping and management of lipoprotein X syndrome. <i>Journal of Clinical Lipidology</i> , 2020 , 14, 850-858	4.9	1
746	Risk Alleles, Cardiac Markers, and Risk of ESKD in African Americans: The Atherosclerosis Risk in Communities Study. <i>Kidney Medicine</i> , 2020 , 2, 502-504	2.8	0
745	Effect of High-Dose Omega-3 Fatty Acids vs Corn Oil on Major Adverse Cardiovascular Events in Patients at High Cardiovascular Risk: The STRENGTH Randomized Clinical Trial. <i>JAMA - Journal of the American Medical Association</i> , 2020 , 324, 2268-2280	27.4	209
744	Lipoprotein(a) and Family History Predict Cardiovascular Disease Risk. <i>Journal of the American College of Cardiology</i> , 2020 , 76, 781-793	15.1	19
743	Sex Hormones and Incident Heart Failure in Men and Postmenopausal Women: The Atherosclerosis Risk in Communities Study. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2020 , 105,	5.6	13
742	Molecular Signature of Multisystem Cardiometabolic Stress and Its Association With Prognosis. <i>JAMA Cardiology</i> , 2020 , 5, 1144-1153	16.2	4

741	Combining Biomarkers and Imaging for Short-Term Assessment of Cardiovascular Disease Risk in Apparently Healthy Adults. <i>Journal of the American Heart Association</i> , 2020 , 9, e015410	6	6
740	Fibrosis and Inflammatory Markers and Long-Term Risk of Peripheral Artery Disease: The ARIC Study. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2020 , 40, 2322-2331	9.4	12
739	Temporal Trends in E-Cigarette Use Among U.S. Adults: Behavioral Risk Factor Surveillance System, 2016 to 2018. <i>American Journal of Medicine</i> , 2020 , 133, e508-e511	2.4	18
738	High-Sensitivity Cardiac Troponin I and T for Cardiovascular Risk Stratification in Adults With Diabetes. <i>Diabetes Care</i> , 2020 , 43, e144-e146	14.6	6
737	Statin Prescription Rates, Adherence, and Associated Clinical Outcomes Among Women with PAD and ICVD. <i>Cardiovascular Drugs and Therapy</i> , 2020 , 34, 745-754	3.9	5
736	Zero Coronary Artery Calcium Score: Desirable, but Enough?. <i>Circulation</i> , 2020 , 142, 917-919	16.7	7
735	Evaluation of Aspirin and Statin Therapy Use and Adherence in Patients With Premature Atherosclerotic Cardiovascular Disease. <i>JAMA Network Open</i> , 2020 , 3, e2011051	10.4	18
734	Dynamic incorporation of multiple in silico functional annotations empowers rare variant association analysis of large whole-genome sequencing studies at scale. <i>Nature Genetics</i> , 2020 , 52, 969-983	36.3	33
733	Shared Decisions: A Qualitative Study on Clinician and Patient Perspectives on Statin Therapy and Statin-Associated Side Effects. <i>Journal of the American Heart Association</i> , 2020 , 9, e017915	6	8
732	Replacing Saturated Fat With Unsaturated Fat in Western Diet Reduces Foamy Monocytes and Atherosclerosis in Male Mice. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2020 , 40, 72-85	9.4	9
731	Spotlight from the American Society for Preventive Cardiology on Key Features of the 2018 AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA Guidelines on the Management of Blood Cholesterol. <i>American Journal of Cardiovascular Drugs</i> , 2020 , 20, 1-9	4	5
730	Bempedoic acid plus ezetimibe fixed-dose combination in patients with hypercholesterolemia and high CVD risk treated with maximally tolerated statin therapy. <i>European Journal of Preventive Cardiology</i> , 2020 , 27, 593-603	3.9	107
729	Association Between Circulating Troponin Concentrations, Left Ventricular Systolic and Diastolic Functions, and Incident Heart Failure in Older Adults. <i>JAMA Cardiology</i> , 2019 , 4, 997-1006	16.2	20
728	Circulating Monocyte Chemoattractant Protein-1 and Risk of Stroke: Meta-Analysis of Population-Based Studies Involving 17 180 Individuals. <i>Circulation Research</i> , 2019 , 125, 773-782	15.7	47
727	Premorbid levels of high-sensitivity cardiac troponin T and natriuretic peptide and prognosis after incident myocardial infarction. <i>American Heart Journal</i> , 2019 , 216, 62-73	4.9	3
726	Reply: Ischemic Event Reduction and Triglycerides. <i>Journal of the American College of Cardiology</i> , 2019 , 74, 1849-1850	15.1	8
725	Multiancestry Genome-Wide Association Study of Lipid Levels Incorporating Gene-Alcohol Interactions. <i>American Journal of Epidemiology</i> , 2019 , 188, 1033-1054	3.8	39
724	The Use of Risk Enhancing Factors to Personalize ASCVD Risk Assessment: Evidence and Recommendations from the 2018 AHA/ACC Multi-society Cholesterol Guidelines. <i>Current Cardiovascular Risk Reports</i> , 2019 , 13, 1	0.9	6

723	Use of Guideline-Recommended Risk Reduction Strategies Among Patients With Diabetes and Atherosclerotic Cardiovascular Disease. <i>Circulation</i> , 2019 , 140, 618-620	16.7	46
722	Effects of Icosapent Ethyl on Total Ischemic Events: From REDUCE-IT. <i>Journal of the American College of Cardiology</i> , 2019 , 73, 2791-2802	15.1	152
721	Associations of High-Sensitivity Cardiac Troponin and Natriuretic Peptide With Subsequent Risk of Infection in Persons Without Cardiovascular Disease: The Atherosclerosis Risk in Communities Study. <i>American Journal of Epidemiology</i> , 2019 , 188, 2146-2155	3.8	2
720	Association Between Lipid Testing and Statin Adherence in the Veterans Affairs Health System. <i>American Journal of Medicine</i> , 2019 , 132, e693-e700	2.4	7
719	Letter by Wu and Ballantyne Regarding Article, "Protein Kinase C α Activating Transcription Factor 2-Mediated CD36 Expression and Foam Cell Formation of Ly6C Cells Contributes to Atherosclerosis". <i>Circulation</i> , 2019 , 139, 2077-2078	16.7	
718	Metabolomic Pattern Predicts Incident Coronary Heart Disease. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2019 , 39, 1475-1482	9.4	23
717	Relation of Isolated Systolic Hypertension and Pulse Pressure to High-Sensitivity Cardiac Troponin-T and N-Terminal pro-B-Type Natriuretic Peptide in Older Adults (from the Atherosclerosis Risk in Communities Study). <i>American Journal of Cardiology</i> , 2019 , 124, 245-252	3	8
716	Subsequent Event Risk in Individuals With Established Coronary Heart Disease. <i>Circulation Genomic and Precision Medicine</i> , 2019 , 12, e002470	5.2	13
715	Association of Chromosome 9p21 With Subsequent Coronary Heart Disease Events. <i>Circulation Genomic and Precision Medicine</i> , 2019 , 12, e002471	5.2	14
714	ApoB, small-dense LDL-C, Lp(a), LpPLA activity, and cognitive change. <i>Neurology</i> , 2019 , 92, e2580-e2593	6.5	9
713	High-Sensitivity Troponin I and Incident Coronary Events, Stroke, Heart Failure Hospitalization, and Mortality in the ARIC Study. <i>Circulation</i> , 2019 , 139, 2642-2653	16.7	99
712	Understanding by General Providers of the Echocardiogram Report. <i>American Journal of Cardiology</i> , 2019 , 124, 296-302	3	0
711	Eligibility and Cost for Icosapent Ethyl Based on the REDUCE-IT Trial. <i>Circulation</i> , 2019 , 139, 1341-1343	16.7	13
710	Central and peripheral pulse wave velocity and subclinical myocardial stress and damage in older adults. <i>PLoS ONE</i> , 2019 , 14, e0212892	3.7	9
709	Reproducibility and Variability of Protein Analytes Measured Using a Multiplexed Modified Aptamer Assay. <i>Journal of Applied Laboratory Medicine</i> , 2019 , 4, 30-39	2	18
708	Safety and Efficacy of Bempedoic Acid to Reduce LDL Cholesterol. <i>New England Journal of Medicine</i> , 2019 , 380, 1022-1032	59.2	265
707	Multi-ancestry genome-wide gene-smoking interaction study of 387,272 individuals identifies new loci associated with serum lipids. <i>Nature Genetics</i> , 2019 , 51, 636-648	36.3	59
706	Cancer Survivorship and Subclinical Myocardial Damage. <i>American Journal of Epidemiology</i> , 2019 , 188, 2188-2195	3.8	5

705	Icosapent Ethyl Effects on Fatty Acid Profiles in Statin-Treated Patients With High Triglycerides: The Randomized, Placebo-controlled ANCHOR Study. <i>Cardiology and Therapy</i> , 2019 , 8, 79-90	2.8	12
704	Sleep apnea and galectin-3: possible sex-specific relationship. <i>Sleep and Breathing</i> , 2019 , 23, 1107-1114	3.1	3
703	Plasma Galectin-3 and Sonographic Measures of Carotid Atherosclerosis in the Atherosclerosis Risk in Communities Study. <i>Angiology</i> , 2019 , 70, 47-55	2.1	9
702	Icosapent ethyl reduces atherogenic markers in high-risk statin-treated patients with stage 3 chronic kidney disease and high triglycerides. <i>Postgraduate Medicine</i> , 2019 , 131, 390-396	3.7	4
701	Reduction in First and Total Ischemic Events With Icosapent Ethyl Across Baseline Triglyceride Tertiles. <i>Journal of the American College of Cardiology</i> , 2019 , 74, 1159-1161	15.1	52
700	Effects of Icosapent Ethyl (Eicosapentaenoic Acid Ethyl Ester) on Atherogenic Lipid/Lipoprotein, Apolipoprotein, and Inflammatory Parameters in Patients With Elevated High-Sensitivity C-Reactive Protein (from the ANCHOR Study). <i>American Journal of Cardiology</i> , 2019 , 124, 696-701	3	24
699	Subclinical Cardiovascular Disease and Fall Risk in Older Adults: Results From the Atherosclerosis Risk in Communities Study. <i>Journal of the American Geriatrics Society</i> , 2019 , 67, 1795-1802	5.6	5
698	Very High-Risk ASCVD and Eligibility for Nonstatin Therapies Based on the 2018 AHA/ACC Cholesterol Guidelines. <i>Journal of the American College of Cardiology</i> , 2019 , 74, 712-714	15.1	10
697	High-Sensitive Troponin T, Natriuretic Peptide, and Cognitive Change. <i>Journal of the American Geriatrics Society</i> , 2019 , 67, 2353-2361	5.6	2
696	Preventive Cardiology as a Subspecialty of Cardiovascular Medicine: JACC Council Perspectives. <i>Journal of the American College of Cardiology</i> , 2019 , 74, 1926-1942	15.1	19
695	Incorporation of Biomarkers Into Risk Assessment for Allocation of Antihypertensive Medication According to the 2017 ACC/AHA High Blood Pressure Guideline: A Pooled Cohort Analysis. <i>Circulation</i> , 2019 , 140, 2076-2088	16.7	23
694	Statin use in carnitine palmitoyltransferase II deficiency. <i>Journal of Clinical Lipidology</i> , 2019 , 13, 550-553	4.9	1
693	Multi-ancestry sleep-by-SNP interaction analysis in 126,926 individuals reveals lipid loci stratified by sleep duration. <i>Nature Communications</i> , 2019 , 10, 5121	17.4	31
692	Poststatin Lipid Therapeutics: A Review. <i>Methodist DeBakey Cardiovascular Journal</i> , 2019 , 15, 32-38	2.1	6
691	The use of structured data elements to identify ASCVD patients with statin-associated side effects: Insights from the Department of Veterans Affairs. <i>Journal of Clinical Lipidology</i> , 2019 , 13, 797-803.e1	4.9	16
690	Response by Jia et al to Letter Regarding Article, "High-Sensitivity Troponin I and Incident Coronary Events, Stroke, Heart Failure Hospitalization, and Mortality in the ARIC Study". <i>Circulation</i> , 2019 , 140, e772-e773	16.7	2
689	Relationship of extracellular volume assessed on cardiac magnetic resonance and serum cardiac troponins and natriuretic peptides with heart failure outcomes. <i>Scientific Reports</i> , 2019 , 9, 20168	4.9	6
688	Myocardial Extracellular Volume Fraction Adds Prognostic Information Beyond Myocardial Replacement Fibrosis. <i>Circulation: Cardiovascular Imaging</i> , 2019 , 12, e009535	3.9	25

687	Future Directions in the Use of Biomarkers for Prevention of Cardiovascular Disease 2019 , 171-177		
686	Association of Cardiac Injury and Malignant Left Ventricular Hypertrophy With Risk of Heart Failure in African Americans: The Jackson Heart Study. <i>JAMA Cardiology</i> , 2019 , 4, 51-58	16.2	24
685	Applicability and Cost Implications for Proprotein Convertase Subtilisin/Kexin Type 9 Inhibitors Based on the ODYSSEY Outcomes Trial. <i>Circulation</i> , 2019 , 139, 410-412	16.7	9
684	Cardiovascular Risk Reduction with Icosapent Ethyl for Hypertriglyceridemia. <i>New England Journal of Medicine</i> , 2019 , 380, 11-22	59.2	1316
683	Safety and efficacy of mipomersen in patients with heterozygous familial hypercholesterolemia. <i>Atherosclerosis</i> , 2019 , 280, 109-117	3.1	28
682	Association of Body Mass Index With Risk Factor Optimization and Guideline-Directed Medical Therapy in US Veterans With Cardiovascular Disease. <i>Circulation: Cardiovascular Quality and Outcomes</i> , 2019 , 12, e004817	5.8	1
681	Lipoprotein(a) levels and risk of cardiovascular disease events in individuals with diabetes mellitus or prediabetes: The Atherosclerosis Risk in Communities study. <i>Atherosclerosis</i> , 2019 , 282, 52-56	3.1	25
680	Bempedoic Acid (ETC-1002): A Current Review. <i>Cardiology Clinics</i> , 2018 , 36, 257-264	2.5	35
679	Statin prescription rates and their facility-level variation in patients with peripheral artery disease and ischemic cerebrovascular disease: Insights from the Department of Veterans Affairs. <i>Vascular Medicine</i> , 2018 , 23, 232-240	3.3	31
678	Usefulness of Lipoprotein-Associated Phospholipase A Activity and C-Reactive Protein in Identifying High-Risk Smokers for Atherosclerotic Cardiovascular Disease (from the Atherosclerosis Risk in Communities Study). <i>American Journal of Cardiology</i> , 2018 , 121, 1056-1064	3	8
677	Six-Year Changes in Physical Activity and the Risk of Incident Heart Failure: ARIC Study. <i>Circulation</i> , 2018 , 137, 2142-2151	16.7	29
676	Efficacy and Safety of Alirocumab in High-Risk Patients With Clinical Atherosclerotic Cardiovascular Disease and/or Heterozygous Familial Hypercholesterolemia (from 5 Placebo-Controlled ODYSSEY Trials). <i>American Journal of Cardiology</i> , 2018 , 121, 940-948	3	13
675	Association of Resting Heart Rate and Temporal Changes in Heart Rate With Outcomes in Participants of the Atherosclerosis Risk in Communities Study. <i>JAMA Cardiology</i> , 2018 , 3, 200-206	16.2	28
674	Relation of Lifestyle Factors and Life's Simple 7 Score to Temporal Reduction in Troponin Levels Measured by a High-Sensitivity Assay (from the Atherosclerosis Risk in Communities Study). <i>American Journal of Cardiology</i> , 2018 , 121, 430-436	3	5
673	SES, Heart Failure, and N-terminal Pro-b-type Natriuretic Peptide: The Atherosclerosis Risk in Communities Study. <i>American Journal of Preventive Medicine</i> , 2018 , 54, 229-236	6.1	9
672	Prevention of "Failure": Is It a Failure of Prevention?. <i>Circulation</i> , 2018 , 137, 106-108	16.7	7
671	Association of lipoprotein-associated phospholipase A and risk of incident atrial fibrillation: Findings from 3 cohorts. <i>American Heart Journal</i> , 2018 , 197, 62-69	4.9	3
670	Traditional and nontraditional glycemic markers and risk of peripheral artery disease: The Atherosclerosis Risk in Communities (ARIC) study. <i>Atherosclerosis</i> , 2018 , 274, 86-93	3.1	14

669	The association of mid-to late-life systemic inflammation with white matter structure in older adults: The Atherosclerosis Risk in Communities Study. <i>Neurobiology of Aging</i> , 2018 , 68, 26-33	5.6	34
668	Short-Term Global Cardiovascular Disease Risk Prediction in Older Adults. <i>Journal of the American College of Cardiology</i> , 2018 , 71, 2527-2536	15.1	29
667	Lipid Effects of Icosapent Ethyl in Women with Diabetes Mellitus and Persistent High Triglycerides on Statin Treatment: ANCHOR Trial Subanalysis. <i>Journal of Women's Health</i> , 2018 , 27, 1170-1176	3	9
666	High-sensitivity cardiac troponin and natriuretic peptide with risk of lower-extremity peripheral artery disease: the Atherosclerosis Risk in Communities (ARIC) Study. <i>European Heart Journal</i> , 2018 , 39, 2412-2419	9.5	34
665	Patient-Specific Flow Descriptors and Normalized wall index in Peripheral Artery Disease: a Preliminary Study. <i>Computer Methods in Biomechanics and Biomedical Engineering: Imaging and Visualization</i> , 2018 , 6, 119-127	0.9	6
664	Association of Lipoprotein(a) With Risk of Recurrent Ischemic Events Following Acute Coronary Syndrome: Analysis of the dal-Outcomes Randomized Clinical Trial. <i>JAMA Cardiology</i> , 2018 , 3, 164-168	16.2	51
663	Health Care Resource Utilization for Outpatient Cardiovascular Disease and Diabetes Care Delivery Among Advanced Practice Providers and Physician Providers in Primary Care. <i>Population Health Management</i> , 2018 , 21, 209-216	1.8	23
662	Plasma galectin-3 levels are associated with the risk of incident chronic kidney disease. <i>Kidney International</i> , 2018 , 93, 252-259	9.9	32
661	Association of midlife lipids with 20-year cognitive change: A cohort study. <i>Alzheimer's and Dementia</i> , 2018 , 14, 167-177	1.2	48
660	Are All Benefits and Harms Equal?. <i>Journal of the American College of Cardiology</i> , 2018 , 72, 819-820	15.1	
659	Clinical Genetic Testing for Familial Hypercholesterolemia: JACC Scientific Expert Panel. <i>Journal of the American College of Cardiology</i> , 2018 , 72, 662-680	15.1	215
658	Effect of Infusion of High-Density Lipoprotein Mimetic Containing Recombinant Apolipoprotein A-I Milano on Coronary Disease in Patients With an Acute Coronary Syndrome in the MILANO-PILOT Trial: A Randomized Clinical Trial. <i>JAMA Cardiology</i> , 2018 , 3, 806-814	16.2	84
657	Variation in Lipid-Lowering Therapy Use in Patients With Low-Density Lipoprotein Cholesterol \geq 190 mg/dL: Insights From the National Cardiovascular Data Registry-Practice Innovation and Clinical Excellence Registry. <i>Circulation: Cardiovascular Quality and Outcomes</i> , 2018 , 11, e004652	5.8	25
656	Orthostatic Hypotension and Risk of Clinical and Subclinical Cardiovascular Disease in Middle-Aged Adults. <i>Journal of the American Heart Association</i> , 2018 , 7,	6	30
655	Modulation of the interleukin-6 signalling pathway and incidence rates of atherosclerotic events and all-cause mortality: analyses from the Canakinumab Anti-Inflammatory Thrombosis Outcomes Study (CANTOS). <i>European Heart Journal</i> , 2018 , 39, 3499-3507	9.5	233
654	Assessment of omega-3 carboxylic acids in statin-treated patients with high levels of triglycerides and low levels of high-density lipoprotein cholesterol: Rationale and design of the STRENGTH trial. <i>Clinical Cardiology</i> , 2018 , 41, 1281-1288	3.3	134
653	Efficacy and safety of bempedoic acid added to ezetimibe in statin-intolerant patients with hypercholesterolemia: A randomized, placebo-controlled study. <i>Atherosclerosis</i> , 2018 , 277, 195-203	3.1	147
652	Discovery, fine-mapping, and conditional analyses of genetic variants associated with C-reactive protein in multiethnic populations using the Metabochip in the Population Architecture using Genomics and Epidemiology (PAGE) study. <i>Human Molecular Genetics</i> , 2018 , 27, 2940-2953	5.6	8

651	Critical role of integrin CD11c in splenic dendritic cell capture of missing-self CD47 cells to induce adaptive immunity. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2018 , 115, 6786-6791	11.5	32
650	Ticagrelor Use in Acute Myocardial Infarction: Insights From the National Cardiovascular Data Registry. <i>Journal of the American Heart Association</i> , 2018 , 7,	6	15
649	Effectiveness of NPs and PAs in managing diabetes and cardiovascular disease. <i>JAAPA: Official Journal of the American Academy of Physician Assistants</i> , 2018 , 31, 39-45	0.8	9
648	Lipoprotein-associated phospholipase A and risk of incident peripheral arterial disease: Findings from The Atherosclerosis Risk in Communities study (ARIC). <i>Atherosclerosis</i> , 2018 , 268, 12-18	3.1	10
647	Lipoprotein(a) and abdominal aortic aneurysm risk: The Atherosclerosis Risk in Communities study. <i>Atherosclerosis</i> , 2018 , 268, 63-67	3.1	11
646	Weight History and Subclinical Myocardial Damage. <i>Clinical Chemistry</i> , 2018 , 64, 201-209	5.5	7
645	Relationship of C-reactive protein reduction to cardiovascular event reduction following treatment with canakinumab: a secondary analysis from the CANTOS randomised controlled trial. <i>Lancet, The</i> , 2018 , 391, 319-328	40	430
644	Facility-Level Variations in Kidney Disease Care among Veterans with Diabetes and CKD. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2018 , 13, 1842-1850	6.9	9
643	Prospective Study of Endogenous Hormones and Incidence of Venous Thromboembolism: The Atherosclerosis Risk in Communities Study. <i>Thrombosis and Haemostasis</i> , 2018 , 118, 1940-1950	7	9
642	Effect of Evolocumab on Coronary Plaque Composition. <i>Journal of the American College of Cardiology</i> , 2018 , 72, 2012-2021	15.1	56
641	Genome Analyses of >200,000 Individuals Identify 58 Loci for Chronic Inflammation and Highlight Pathways that Link Inflammation and Complex Disorders. <i>American Journal of Human Genetics</i> , 2018 , 103, 691-706	11	151
640	Diagnostic Performance of 1,5-Anhydroglucitol Compared to 2-H Glucose in the Atherosclerosis Risk in Communities Study. <i>Clinical Chemistry</i> , 2018 , 64, 1536-1537	5.5	3
639	Cardiovascular Disease Prevention: Training Opportunities, the Challenges, and Future Directions. <i>Current Atherosclerosis Reports</i> , 2018 , 20, 35	6	8
638	Remnant-Like Particle Cholesterol, Low-Density Lipoprotein Triglycerides, and Incident Cardiovascular Disease. <i>Journal of the American College of Cardiology</i> , 2018 , 72, 156-169	15.1	71
637	Case reports of proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibition nonresponse. <i>Journal of Clinical Lipidology</i> , 2018 , 12, 1141-1145	4.9	6
636	Aldosterone Does Not Predict Cardiovascular Events Following Acute Coronary Syndrome in Patients Initially Without Heart Failure. <i>Journal of the American Heart Association</i> , 2017 , 6,	6	2
635	Myocardial Injury, Obesity, and the Obesity Paradox: The ARIC Study. <i>JACC: Heart Failure</i> , 2017 , 5, 56-63	7.9	18
634	Usefulness of Icosapent Ethyl (Eicosapentaenoic Acid Ethyl Ester) in Women to Lower Triglyceride Levels (Results from the MARINE and ANCHOR Trials). <i>American Journal of Cardiology</i> , 2017 , 119, 397-403	3	12

633	Serum vitamin D and change in lipid levels over 5y: The Atherosclerosis Risk in Communities study. <i>Nutrition</i> , 2017 , 38, 85-93	4.8	19
632	Practical Approaches for Whole-Genome Sequence Analysis of Heart- and Blood-Related Traits. <i>American Journal of Human Genetics</i> , 2017 , 100, 205-215	11	29
631	Looking Back at Look AHEAD Through the Lens of Recent Diabetes Outcome Trials. <i>Circulation</i> , 2017 , 135, 720-723	16.7	6
630	Assessing Cardiovascular Risk and Testing in Type 2 Diabetes. <i>Current Cardiology Reports</i> , 2017 , 19, 19	4.2	12
629	Postprandial lipemia and the risk of coronary heart disease and stroke: the Atherosclerosis Risk in Communities (ARIC) Study. <i>BMJ Open Diabetes Research and Care</i> , 2017 , 5, e000335	4.5	11
628	Association between high-sensitivity troponin T and cardiovascular risk in individuals with and without metabolic syndrome: The ARIC study. <i>European Journal of Preventive Cardiology</i> , 2017 , 24, 628-638	3.8	13
627	Adoption of the 2013 American College of Cardiology/American Heart Association Cholesterol Management Guideline in Cardiology Practices Nationwide. <i>JAMA Cardiology</i> , 2017 , 2, 361-369	16.2	64
626	BNP and obesity in acute decompensated heart failure with preserved vs. reduced ejection fraction: The Atherosclerosis Risk in Communities Surveillance Study. <i>International Journal of Cardiology</i> , 2017 , 233, 61-66	3.2	24
625	Endothelial LRP1 regulates metabolic responses by acting as a co-activator of PPAR α . <i>Nature Communications</i> , 2017 , 8, 14960	17.4	34
624	Physical Activity, Obesity, and Subclinical Myocardial Damage. <i>JACC: Heart Failure</i> , 2017 , 5, 377-384	7.9	13
623	Comparative effects of cholesteryl ester transfer protein inhibition, statin or ezetimibe on lipid factors: The ACCENTUATE trial. <i>Atherosclerosis</i> , 2017 , 261, 12-18	3.1	21
622	A Multiregional, Randomized Evaluation of the Lipid-Modifying Efficacy and Tolerability of Anacetrapib Added to Ongoing Statin Therapy in Patients With Hypercholesterolemia or Low High-Density Lipoprotein Cholesterol. <i>American Journal of Cardiology</i> , 2017 , 120, 569-576	3	7
621	The Upregulation of Integrin α CD11d/CD18) on Inflammatory Macrophages Promotes Macrophage Retention in Vascular Lesions and Development of Atherosclerosis. <i>Journal of Immunology</i> , 2017 , 198, 4855-4867	5.3	36
620	Dyslipidaemia: PCSK9 inhibitors and foamy monocytes in familial hypercholesterolaemia. <i>Nature Reviews Cardiology</i> , 2017 , 14, 385-386	14.8	16
619	Estimation of Eligibility for Proprotein Convertase Subtilisin/Kexin Type 9 Inhibitors and Associated Costs Based on the FOURIER Trial (Further Cardiovascular Outcomes Research With PCSK9 Inhibition in Subjects With Elevated Risk): Insights From the Department of Veterans Affairs. <i>Circulation</i> , 2017 , 135, 2572-2574	16.7	37
618	Access to Nonstatin Lipid-Lowering Therapies in Patients at High Risk of Atherosclerotic Cardiovascular Disease. <i>Circulation</i> , 2017 , 135, 2204-2206	16.7	28
617	Lipoprotein (a) levels and Risk of Cardiovascular Disease Events in Diabetes Mellitus and Prediabetes: The Atherosclerosis Risk in Communities Study. <i>Journal of Clinical Lipidology</i> , 2017 , 11, 779-780	4.8	19
616	Systolic and pulse pressure associate with incident knee osteoarthritis: data from the Osteoarthritis Initiative. <i>Clinical Rheumatology</i> , 2017 , 36, 2121-2128	3.9	21

615	Relations between lipoprotein(a) concentrations, LPA genetic variants, and the risk of mortality in patients with established coronary heart disease: a molecular and genetic association study. <i>Lancet Diabetes and Endocrinology</i> , 2017 , 5, 534-543	18.1	69
614	The association of lipoprotein(a) with incident heart failure hospitalization: Atherosclerosis Risk in Communities study. <i>Atherosclerosis</i> , 2017 , 262, 131-137	3.1	14
613	An Promoter Polymorphism Associated With Elevated N-Terminal pro-B-Type Natriuretic Peptide and Lower Blood Pressure, Hypertension, and Mortality. <i>Journal of the American Heart Association</i> , 2017 , 6,	6	26
612	Multimodality Strategy for Cardiovascular Risk Assessment: Performance in 2 Population-Based Cohorts. <i>Circulation</i> , 2017 , 135, 2119-2132	16.7	51
611	Rationale and design of REDUCE-IT: Reduction of Cardiovascular Events with Icosapent Ethyl-Intervention Trial. <i>Clinical Cardiology</i> , 2017 , 40, 138-148	3.3	114
610	High-Sensitivity Cardiac Troponin T (hs-cTnT) as a Predictor of Incident Diabetes in the Atherosclerosis Risk in Communities Study. <i>Diabetes Care</i> , 2017 , 40, 261-269	14.6	18
609	Health disparities among adult patients with a phenotypic diagnosis of familial hypercholesterolemia in the CASCADE-FH patient registry. <i>Atherosclerosis</i> , 2017 , 267, 19-26	3.1	36
608	Exome-wide association study of plasma lipids in >300,000 individuals. <i>Nature Genetics</i> , 2017 , 49, 1758-1766	310	
607	Midlife systemic inflammatory markers are associated with late-life brain volume: The ARIC study. <i>Neurology</i> , 2017 , 89, 2262-2270	6.5	59
606	Sedentary Behavior and Subclinical Cardiac Injury: Results From the Dallas Heart Study. <i>Circulation</i> , 2017 , 136, 1451-1453	16.7	6
605	Skeletal muscle inflammation and insulin resistance in obesity. <i>Journal of Clinical Investigation</i> , 2017 , 127, 43-54	15.9	242
604	Effect of interleukin-1 inhibition with canakinumab on incident lung cancer in patients with atherosclerosis: exploratory results from a randomised, double-blind, placebo-controlled trial. <i>Lancet, The</i> , 2017 , 390, 1833-1842	40	634
603	Antiinflammatory Therapy with Canakinumab for Atherosclerotic Disease. <i>New England Journal of Medicine</i> , 2017 , 377, 1119-1131	59.2	3877
602	2017 Focused Update of the 2016 ACC Expert Consensus Decision Pathway on the Role of Non-Statin Therapies for LDL-Cholesterol Lowering in the Management of Atherosclerotic Cardiovascular Disease Risk: A Report of the American College of Cardiology Task Force on Expert Consensus Decision Pathways. <i>Circulation</i> , 2017 , 135, 1785-1802	15.1	247
601	Association of Elevated Triglycerides and Atherogenic Lipoproteins with Incident Cardiovascular Diseases: Insights from Genetic Data in the Atherosclerosis Risk in Communities Study. <i>Journal of Clinical Lipidology</i> , 2017 , 11, 788	4.9	2
600	Galectin-3 and incidence of atrial fibrillation: The Atherosclerosis Risk in Communities (ARIC) study. <i>American Heart Journal</i> , 2017 , 192, 19-25	4.9	28
599	Association of High-Density Lipoprotein-Cholesterol Versus Apolipoprotein A-I With Risk of Coronary Heart Disease: The European Prospective Investigation Into Cancer-Norfolk Prospective Population Study, the Atherosclerosis Risk in Communities Study, and the Women's Health Study. <i>Journal of the American Heart Association</i> , 2017 , 6,	6	9
598	Associations of Lipoprotein(a) Levels With Incident Atrial Fibrillation and Ischemic Stroke: The ARIC (Atherosclerosis Risk in Communities) Study. <i>Journal of the American Heart Association</i> , 2017 , 6,	6	23

597	Galectin-3 and Venous Thromboembolism Incidence: the Atherosclerosis Risk in Communities (ARIC) Study. <i>Research and Practice in Thrombosis and Haemostasis</i> , 2017 , 1, 223-230	5.1	10
596	Midlife Systemic Inflammation, Late-Life White Matter Integrity, and Cerebral Small Vessel Disease: The Atherosclerosis Risk in Communities Study. <i>Stroke</i> , 2017 , 48, 3196-3202	6.7	61
595	Lipoprotein(a) and coronary atheroma progression rates during long-term high-intensity statin therapy: Insights from SATURN. <i>Atherosclerosis</i> , 2017 , 263, 137-144	3.1	29
594	Pediatric Familial Hypercholesterolemia: Children and Adolescents Enrolled in the CAscade SCreening for Awareness. <i>Journal of Clinical Lipidology</i> , 2017 , 11, 812-813	4.9	2
593	Lipid-Modifying Efficacy and Tolerability of Anacetrapib Added to Ongoing Statin Therapy in Patients with Hypercholesterolemia or Low High-Density Lipoprotein Cholesterol. <i>American Journal of Cardiology</i> , 2017 , 119, 388-396	3	11
592	Evaluation of the efficacy, safety and glycaemic effects of evolocumab (AMG 145) in hypercholesterolaemic patients stratified by glycaemic status and metabolic syndrome. <i>Diabetes, Obesity and Metabolism</i> , 2017 , 19, 98-107	6.7	41
591	Galectin-3 and the incidence of abdominal aortic aneurysm: the atherosclerosis risk in communities (ARIC) study. <i>American Journal of Cardiovascular Disease</i> , 2017 , 7, 114-121	0.9	2
590	Effect of the BET Protein Inhibitor, RVX-208, on Progression of Coronary Atherosclerosis: Results of the Phase 2b, Randomized, Double-Blind, Multicenter, ASSURE Trial. <i>American Journal of Cardiovascular Drugs</i> , 2016 , 16, 55-65	4	67
589	Postprandial Monocyte Activation in Individuals With Metabolic Syndrome. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2016 , 101, 4195-4204	5.6	29
588	US physician practices for diagnosing familial hypercholesterolemia: data from the CASCADE-FH registry. <i>Journal of Clinical Lipidology</i> , 2016 , 10, 1223-9	4.9	41
587	Alcohol Consumption and Cardiac Biomarkers: The Atherosclerosis Risk in Communities (ARIC) Study. <i>Clinical Chemistry</i> , 2016 , 62, 1202-10	5.5	10
586	Treatment With Dalcetrapib Modifies the Relationship Between High-Density Lipoprotein Cholesterol and C-Reactive Protein. <i>Journal of the American College of Cardiology</i> , 2016 , 68, 2488-2490	15.1	4
585	Severe Hypoglycemia and Elevated High-Sensitivity Cardiac Troponin T in Older Adults With Diabetes: The ARIC Study. <i>Journal of the American College of Cardiology</i> , 2016 , 68, 1370-1	15.1	11
584	Biomarkers and degree of atherosclerosis are independently associated with incident atherosclerotic cardiovascular disease in a primary prevention cohort: The ARIC study. <i>Atherosclerosis</i> , 2016 , 253, 156-163	3.1	9
583	Obesity and Subtypes of Incident Cardiovascular Disease. <i>Journal of the American Heart Association</i> , 2016 , 5,	6	89
582	Practice-Level Variation in Statin Use Among Patients With Diabetes: Insights From the PINNACLE Registry. <i>Journal of the American College of Cardiology</i> , 2016 , 68, 1368-9	15.1	34
581	Icosapent ethyl: Eicosapentaenoic acid concentration and triglyceride-lowering effects across clinical studies. <i>Prostaglandins and Other Lipid Mediators</i> , 2016 , 125, 57-64	3.7	25
580	Effect of Evolocumab on Progression of Coronary Disease in Statin-Treated Patients: The GLAGOV Randomized Clinical Trial. <i>JAMA - Journal of the American Medical Association</i> , 2016 , 316, 2373-2384	27.4	549

579	Six-Year Change in High-Sensitivity Cardiac Troponin T and Risk of Subsequent Coronary Heart Disease, Heart Failure, and Death. <i>JAMA Cardiology</i> , 2016 , 1, 519-28	16.2	72
578	The impact of multiple single day blood pressure readings on cardiovascular risk estimation: The Atherosclerosis Risk in Communities study. <i>European Journal of Preventive Cardiology</i> , 2016 , 23, 1529-36 ^{3,9}		2
577	Defective Association of the Platelet Glycoprotein Ib-IX Complex with the Glycosphingolipid-Enriched Membrane Domain Inhibits Murine Thrombus and Atheroma Formation. <i>Journal of Immunology</i> , 2016 , 197, 288-95	5.3	6
576	Effect of ETC-1002 on Serum Low-Density Lipoprotein Cholesterol in Hypercholesterolemic Patients Receiving Statin Therapy. <i>American Journal of Cardiology</i> , 2016 , 117, 1928-33	3	68
575	Icosapent ethyl (eicosapentaenoic acid ethyl ester): Effects on plasma apolipoprotein C-III levels in patients from the MARINE and ANCHOR studies. <i>Journal of Clinical Lipidology</i> , 2016 , 10, 635-645.e1	4.9	3 ¹
574	Lifestyle Intervention for Weight Loss and Cardiometabolic Changes in the Setting of Glucokinase Regulatory Protein Inhibition: Glucokinase Regulatory Protein-Leu446Pro Variant in Look AHEAD. <i>Circulation: Cardiovascular Genetics</i> , 2016 , 9, 71-8		3
573	Treatment with ETC-1002 alone and in combination with ezetimibe lowers LDL cholesterol in hypercholesterolemic patients with or without statin intolerance. <i>Journal of Clinical Lipidology</i> , 2016 , 10, 556-67	4.9	87
572	Plaque Volume of Carotid Endarterectomy Specimens Measured by 3D Ultrasound Technology. <i>JACC: Cardiovascular Imaging</i> , 2016 , 9, 1118-1119	8.4	2
571	Treatment Gaps in Adults With Heterozygous Familial Hypercholesterolemia in the United States: Data From the CASCADE-FH Registry. <i>Circulation: Cardiovascular Genetics</i> , 2016 , 9, 240-9		126
570	Comparison of PCSK9 Inhibitor Evolocumab vs Ezetimibe in Statin-Intolerant Patients: Design of the Goal Achievement After Utilizing an Anti-PCSK9 Antibody in Statin-Intolerant Subjects 3 (GAUSS-3) Trial. <i>Clinical Cardiology</i> , 2016 , 39, 137-44	3.3	25
569	Genetic Testing in Hyperlipidemia. <i>Endocrinology and Metabolism Clinics of North America</i> , 2016 , 45, 129-40		3
568	The Association of Socioeconomic Status With Subclinical Myocardial Damage, Incident Cardiovascular Events, and Mortality in the ARIC Study. <i>American Journal of Epidemiology</i> , 2016 , 183, 452-61	3.8	19
567	Cardiac ScoreCard: A Diagnostic Multivariate Index Assay System for Predicting a Spectrum of Cardiovascular Disease. <i>Expert Systems With Applications</i> , 2016 , 54, 136-147	7.8	22
566	Case-based educational intervention to assess change in providers' knowledge and attitudes towards the 2013 American College of Cardiology/American Heart Association Cholesterol Management Guideline. <i>Atherosclerosis</i> , 2016 , 246, 115-20	3.1	14
565	Calf muscle perfusion as measured with magnetic resonance imaging to assess peripheral arterial disease. <i>Medical and Biological Engineering and Computing</i> , 2016 , 54, 1667-1681	3.1	9
564	Determinants of minimal elevation in high-sensitivity cardiac troponin T in the general population. <i>Clinical Biochemistry</i> , 2016 , 49, 657-662	3.5	19
563	N-Terminal Pro-Brain Natriuretic Peptide and Heart Failure Risk Among Individuals With and Without Obesity: The Atherosclerosis Risk in Communities (ARIC) Study. <i>Circulation</i> , 2016 , 133, 631-8	16.7	69
562	Natriuretic Peptide and High-Sensitivity Troponin for Cardiovascular Risk Prediction in Diabetes: The Atherosclerosis Risk in Communities (ARIC) Study. <i>Diabetes Care</i> , 2016 , 39, 677-85	14.6	32

561	Abstract 52: Efficacy and Safety of Mipomersen in Patients with Familial Hypercholesterolemia and Inadequately Controlled LDL-C Levels. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2016 , 36,	9.4	2
560	Abstract 138: Contemporary Patterns of Use of Antiplatelet Agents in Patients With Acute Myocardial Infarction: Insight From the National Cardiovascular Data Registry (NCDR). <i>Circulation: Cardiovascular Quality and Outcomes</i> , 2016 , 9,	5.8	1
559	A colitogenic memory CD4+ T cell population mediates gastrointestinal graft-versus-host disease. <i>Journal of Clinical Investigation</i> , 2016 , 126, 3541-55	15.9	24
558	Causal Role of Alcohol Consumption in an Improved Lipid Profile: The Atherosclerosis Risk in Communities (ARIC) Study. <i>PLoS ONE</i> , 2016 , 11, e0148765	3.7	45
557	Influence of cigarette smoking on cardiac biomarkers: the Atherosclerosis Risk in Communities (ARIC) Study. <i>European Journal of Heart Failure</i> , 2016 , 18, 629-37	12.3	24
556	Galectin-3 and Risk of Heart Failure and Death in Blacks and Whites. <i>Journal of the American Heart Association</i> , 2016 , 5,	6	20
555	Meta-analysis of genome-wide association studies of HDL cholesterol response to statins. <i>Journal of Medical Genetics</i> , 2016 , 53, 835-845	5.8	28
554	25-Hydroxyvitamin D Levels and Markers of Subclinical Myocardial Damage and Wall Stress: The Atherosclerosis Risk in Communities Study. <i>Journal of the American Heart Association</i> , 2016 , 5,	6	6
553	P2-415: Association of Baseline Lipids with 20-Year Cognitive Change: The ARIC Neurocognitive Study 2016 , 12, P804-P804		
552	Impact of PCSK9 inhibition on coronary atheroma progression: Rationale and design of Global Assessment of Plaque Regression with a PCSK9 Antibody as Measured by Intravascular Ultrasound (GLAGOV). <i>American Heart Journal</i> , 2016 , 176, 83-92	4.9	32
551	Provider understanding of the 2013 ACC/AHA cholesterol guideline. <i>Journal of Clinical Lipidology</i> , 2016 , 10, 497-504.e4	4.9	54
550	A dataset to assess providers' knowledge and attitudes towards the 2013 American College of Cardiology/American Heart Association Cholesterol Management Guideline. <i>Data in Brief</i> , 2016 , 7, 595-8 ^{1,2}		5
549	Efficacy and Tolerability of Evolocumab vs Ezetimibe in Patients With Muscle-Related Statin Intolerance: The GAUSS-3 Randomized Clinical Trial. <i>JAMA - Journal of the American Medical Association</i> , 2016 , 315, 1580-90	27.4	307
548	2016 ACC Expert Consensus Decision Pathway on the Role of Non-Statins Therapies for LDL-Cholesterol Lowering in the Management of Atherosclerotic Cardiovascular Disease Risk: A Report of the American College of Cardiology Task Force on Clinical Expert Consensus Documents. <i>Journal of the American College of Cardiology</i> , 2016 , 68, 92-125	15.1	303
547	Accuracy of the Atherosclerotic Cardiovascular Risk Equation in a Large, Contemporary, Multiethnic Population. <i>Journal of the American College of Cardiology</i> , 2016 , 67, 2118-2130	15.1	165
546	Diastolic Blood Pressure, Subclinical Myocardial Damage, and Cardiac Events: Implications for Blood Pressure Control. <i>Journal of the American College of Cardiology</i> , 2016 , 68, 1713-1722	15.1	188
545	Natriuretic peptides and integrated risk assessment for cardiovascular disease: an individual-participant-data meta-analysis. <i>Lancet Diabetes and Endocrinology</i> , 2016 , 4, 840-9	18.1	108
544	Comparative effectiveness of outpatient cardiovascular disease and diabetes care delivery between advanced practice providers and physician providers in primary care: Implications for care under the Affordable Care Act. <i>American Heart Journal</i> , 2016 , 181, 74-82	4.9	48

543	Icosapent ethyl (eicosapentaenoic acid ethyl ester): Effects on remnant-like particle cholesterol from the MARINE and ANCHOR studies. <i>Atherosclerosis</i> , 2016 , 253, 81-87	3.1	33
542	Risk Factor Optimization and Guideline-Directed Medical Therapy in US Veterans With Peripheral Arterial and Ischemic Cerebrovascular Disease Compared to Veterans With Coronary Heart Disease. <i>American Journal of Cardiology</i> , 2016 , 118, 1144-1149	3	33
541	Magnetic Resonance Venous Volume Measurements in Peripheral Artery Disease (from ELIMIT). <i>American Journal of Cardiology</i> , 2016 , 118, 1399-1404	3	3
540	On-treatment analysis of the Improved Reduction of Outcomes: Vytorin Efficacy International Trial (IMPROVE-IT). <i>American Heart Journal</i> , 2016 , 182, 89-96	4.9	13
539	Bempedoic Acid (ETC-1002): an Investigational Inhibitor of ATP Citrate Lyase. <i>Current Atherosclerosis Reports</i> , 2016 , 18, 61	6	50
538	Statin Use and Its Facility-Level Variation in Patients With Diabetes: Insight From the Veterans Affairs National Database. <i>Clinical Cardiology</i> , 2016 , 39, 185-91	3.3	31
537	Statins, plasma cholesterol, and risk of Parkinson's disease: a prospective study. <i>Movement Disorders</i> , 2015 , 30, 552-9	7	83
536	Plasma lactate and incident hypertension in the atherosclerosis risk in communities study. <i>American Journal of Hypertension</i> , 2015 , 28, 216-24	2.3	27
535	Lipoprotein associated phospholipase A2 activity, apolipoprotein C3 loss-of-function variants and cardiovascular disease: The Atherosclerosis Risk In Communities Study. <i>Atherosclerosis</i> , 2015 , 241, 641-8 ^{3.1}	3.1	14
534	Circulating Biomarkers and Abdominal Aortic Aneurysm Incidence: The Atherosclerosis Risk in Communities (ARIC) Study. <i>Circulation</i> , 2015 , 132, 578-85	16.7	67
533	High-Sensitivity Cardiac Troponin T and Risk of Hypertension. <i>Circulation</i> , 2015 , 132, 825-33	16.7	62
532	A common variant in the CLDN7/ELP5 locus predicts adiponectin change with lifestyle intervention and improved fitness in obese individuals with diabetes. <i>Physiological Genomics</i> , 2015 , 47, 215-24	3.6	4
531	Implications of the Eighth Joint National Committee Guidelines for the Management of High Blood Pressure for Aging Adults: Atherosclerosis Risk in Communities Study. <i>Hypertension</i> , 2015 , 66, 474-80	8.5	10
530	Foamy monocytes form early and contribute to nascent atherosclerosis in mice with hypercholesterolemia. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2015 , 35, 1787-97	9.4	61
529	Implications for Ezetimibe Therapy Use Based on IMPROVE-IT Criteria. <i>American Journal of Medicine</i> , 2015 , 128, 1253-6	2.4	6
528	Results of bococizumab, a monoclonal antibody against proprotein convertase subtilisin/kexin type 9, from a randomized, placebo-controlled, dose-ranging study in statin-treated subjects with hypercholesterolemia. <i>American Journal of Cardiology</i> , 2015 , 115, 1212-21	3	138
527	FDG-PET imaging for oxidized LDL in stable atherosclerotic disease: a phase II study of safety, tolerability, and anti-inflammatory activity. <i>JACC: Cardiovascular Imaging</i> , 2015 , 8, 493-494	8.4	48
526	The effect of BMS-582949, a P38 mitogen-activated protein kinase (P38 MAPK) inhibitor on arterial inflammation: a multicenter FDG-PET trial. <i>Atherosclerosis</i> , 2015 , 240, 490-6	3.1	54

525	The promise of proprotein convertase subtilisin/kexin 9 inhibitors for the treatment of familial hypercholesterolemia. <i>Current Atherosclerosis Reports</i> , 2015 , 17, 508	6	
524	Efficacy and safety of evolocumab in reducing lipids and cardiovascular events. <i>New England Journal of Medicine</i> , 2015 , 372, 1500-9	59.2	1081
523	Patterns and determinants of temporal change in high-sensitivity cardiac troponin-T: The Atherosclerosis Risk in Communities Cohort Study. <i>International Journal of Cardiology</i> , 2015 , 187, 651-7	3.2	32
522	Eligibility for statin therapy according to new cholesterol guidelines and prevalent use of medication to lower lipid levels in an older US Cohort: the Atherosclerosis Risk in Communities Study Cohort. <i>JAMA Internal Medicine</i> , 2015 , 175, 138-40	11.5	17
521	Recalibration of blood analytes over 25 years in the atherosclerosis risk in communities study: impact of recalibration on chronic kidney disease prevalence and incidence. <i>Clinical Chemistry</i> , 2015 , 61, 938-47	5.5	55
520	Medical Management of Serum Lipids and Coronary Heart Disease. <i>Cardiovascular Medicine</i> , 2015 , 39-55	0.1	
519	N-Terminal Pro-Brain Natriuretic Peptide (NT-proBNP) and Risk of Hypertension in the Atherosclerosis Risk in Communities (ARIC) Study. <i>American Journal of Hypertension</i> , 2015 , 28, 1262-6	2.3	24
518	Postprandial effects on arterial stiffness parameters in healthy young adults. <i>Vascular Medicine</i> , 2015 , 20, 501-8	3.3	8
517	Sex-Specific Association of Sleep Apnea Severity With Subclinical Myocardial Injury, Ventricular Hypertrophy, and Heart Failure Risk in a Community-Dwelling Cohort: The Atherosclerosis Risk in Communities-Sleep Heart Health Study. <i>Circulation</i> , 2015 , 132, 1329-37	16.7	94
516	Icosapent Ethyl (Eicosapentaenoic Acid Ethyl Ester): Effects Upon High-Sensitivity C-Reactive Protein and Lipid Parameters in Patients With Metabolic Syndrome. <i>Metabolic Syndrome and Related Disorders</i> , 2015 , 13, 239-47	2.6	18
515	Ideal Cardiovascular Health During Adult Life and Cardiovascular Structure and Function Among the Elderly. <i>Circulation</i> , 2015 , 132, 1979-89	16.7	38
514	Validity of self-report of lipid medication use: the Atherosclerosis Risk in Communities (ARIC) Study. <i>Atherosclerosis</i> , 2015 , 242, 625-9	3.1	2
513	Prognostic Significance of High-Sensitivity Cardiac Troponin T Concentrations between the Limit of Blank and Limit of Detection in Community-Dwelling Adults: A Metaanalysis. <i>Clinical Chemistry</i> , 2015 , 61, 1524-31	5.5	31
512	Effects of icosapent ethyl on lipoprotein particle concentration and size in statin-treated patients with persistent high triglycerides (the ANCHOR Study). <i>Journal of Clinical Lipidology</i> , 2015 , 9, 377-83	4.9	32
511	Provider Type and Quality of Outpatient Cardiovascular Disease Care: Insights From the NCDR PINNACLE Registry. <i>Journal of the American College of Cardiology</i> , 2015 , 66, 1803-1812	15.1	40
510	The association of liver enzymes with biomarkers of subclinical myocardial damage and structural heart disease. <i>Journal of Hepatology</i> , 2015 , 62, 841-7	13.4	28
509	High-sensitivity troponin T and cardiovascular events in systolic blood pressure categories: atherosclerosis risk in communities study. <i>Hypertension</i> , 2015 , 65, 78-84	8.5	24
508	Gender disparities in evidence-based statin therapy in patients with cardiovascular disease. <i>American Journal of Cardiology</i> , 2015 , 115, 21-6	3	96

507	Development of chagas cardiac manifestations among Texas blood donors. <i>American Journal of Cardiology</i> , 2015 , 115, 113-7	3	24
506	High-sensitivity cardiac troponin T and the risk of incident atrial fibrillation: the Atherosclerosis Risk in Communities (ARIC) study. <i>American Heart Journal</i> , 2015 , 169, 31-8.e3	4.9	49
505	Severity of hypoxia modulates effect of CPAP on myocardial stress as measured by highly sensitive troponin T. <i>Respiratory Research</i> , 2015 , 16, 126	7.3	1
504	Influence of metabolic syndrome factors and insulin resistance on the efficacy of ezetimibe/simvastatin and atorvastatin in patients with metabolic syndrome and atherosclerotic coronary heart disease risk. <i>Lipids in Health and Disease</i> , 2015 , 14, 103	4.4	8
503	Six-year change in high-sensitivity C-reactive protein and risk of diabetes, cardiovascular disease, and mortality. <i>American Heart Journal</i> , 2015 , 170, 380-9	4.9	69
502	Improving Adiponectin Levels in Individuals With Diabetes and Obesity: Insights From Look AHEAD. <i>Diabetes Care</i> , 2015 , 38, 1544-50	14.6	18
501	Genetic testing in hyperlipidemia. <i>Cardiology Clinics</i> , 2015 , 33, 267-75	2.5	4
500	Racial differences in circulating natriuretic peptide levels: the atherosclerosis risk in communities study. <i>Journal of the American Heart Association</i> , 2015 , 4,	6	40
499	Soluble receptor for advanced glycation end products and the risk for incident heart failure: The Atherosclerosis Risk in Communities Study. <i>American Heart Journal</i> , 2015 , 170, 961-7	4.9	32
498	Lipoprotein-associated phospholipase A2, homocysteine, and Alzheimer's disease. <i>Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring</i> , 2015 , 1, 464-71	5.2	16
497	Association of plasma levels of soluble receptor for advanced glycation end products and risk of kidney disease: the Atherosclerosis Risk in Communities study. <i>Nephrology Dialysis Transplantation</i> , 2015 , 30, 77-83	4.3	25
496	sRAGE, inflammation, and risk of atrial fibrillation: results from the Atherosclerosis Risk in Communities (ARIC) Study. <i>Journal of Diabetes and Its Complications</i> , 2015 , 29, 180-5	3.2	18
495	Association of high-sensitivity cardiac troponin T and natriuretic peptide with incident ESRD: the Atherosclerosis Risk in Communities (ARIC) study. <i>American Journal of Kidney Diseases</i> , 2015 , 65, 550-8	7.4	12
494	Frequency and practice-level variation in inappropriate aspirin use for the primary prevention of cardiovascular disease: insights from the National Cardiovascular Disease Registry's Practice Innovation and Clinical Excellence registry. <i>Journal of the American College of Cardiology</i> , 2015 , 65, 111-21	15.1	50
493	Abstract 17499: ETC-1002 Incrementally Lowers Low Density Lipoprotein-cholesterol in Patients With Hypercholesterolemia Receiving Stable Statin Therapy. <i>Circulation</i> , 2015 , 132,	16.7	4
492	Whole-exome sequencing identifies rare and low-frequency coding variants associated with LDL cholesterol. <i>American Journal of Human Genetics</i> , 2014 , 94, 233-45	11	170
491	A 52-week placebo-controlled trial of evolocumab in hyperlipidemia. <i>New England Journal of Medicine</i> , 2014 , 370, 1809-19	59.2	506
490	The ACC/AHA 2013 guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular disease risk in adults: the good the bad and the uncertain: a comparison with ESC/EAS guidelines for the management of dyslipidaemias 2011. <i>European Heart Journal</i> , 2014 , 35, 960-8	9.5	222

489	Long-term effects of maximally intensive statin therapy on changes in coronary atheroma composition: insights from SATURN. <i>European Heart Journal Cardiovascular Imaging</i> , 2014 , 15, 380-8	4.1	111
488	Rationale and design of the familial hypercholesterolemia foundation CAsCade SCReening for Awareness and DEtection of Familial Hypercholesterolemia registry. <i>American Heart Journal</i> , 2014 , 167, 342-349.e17	4.9	63
487	Inflammation versus host defense in obesity. <i>Cell Metabolism</i> , 2014 , 20, 708-709	24.6	9
486	Obesity, subclinical myocardial injury, and incident heart failure. <i>JACC: Heart Failure</i> , 2014 , 2, 600-7	7.9	55
485	Inactivating mutations in NPC1L1 and protection from coronary heart disease. <i>New England Journal of Medicine</i> , 2014 , 371, 2072-82	59.2	307
484	Small dense low-density lipoprotein-cholesterol concentrations predict risk for coronary heart disease: the Atherosclerosis Risk In Communities (ARIC) study. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2014 , 34, 1069-77	9.4	270
483	Lipid lowering with PCSK9 inhibitors. <i>Nature Reviews Cardiology</i> , 2014 , 11, 563-75	14.8	167
482	Review of clinical practice guidelines for the management of LDL-related risk. <i>Journal of the American College of Cardiology</i> , 2014 , 64, 196-206	15.1	43
481	Diabetes mellitus, prediabetes, and incidence of subclinical myocardial damage. <i>Circulation</i> , 2014 , 130, 1374-82	16.7	132
480	Association between lipoprotein associated phospholipase A2 mass and subclinical coronary and carotid atherosclerosis in Retired National Football League players. <i>Atherosclerosis</i> , 2014 , 236, 251-6	3.1	6
479	High-intensity statin therapy alters the natural history of diabetic coronary atherosclerosis: insights from SATURN. <i>Diabetes Care</i> , 2014 , 37, 3114-20	14.6	45
478	Sex-related differences of coronary atherosclerosis regression following maximally intensive statin therapy: insights from SATURN. <i>JACC: Cardiovascular Imaging</i> , 2014 , 7, 1013-22	8.4	40
477	Antiatherosclerotic effects of long-term maximally intensive statin therapy after acute coronary syndrome: insights from Study of Coronary Atheroma by Intravascular Ultrasound: Effect of Rosuvastatin Versus Atorvastatin. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2014 , 34, 2465-72	9.4	33
476	Large multiethnic Candidate Gene Study for C-reactive protein levels: identification of a novel association at CD36 in African Americans. <i>Human Genetics</i> , 2014 , 133, 985-95	6.3	25
475	Validated context-dependent associations of coronary heart disease risk with genotype variation in the chromosome 9p21 region: the Atherosclerosis Risk in Communities study. <i>Human Genetics</i> , 2014 , 133, 1105-16	6.3	14
474	Cardiac and kidney markers for cardiovascular prediction in individuals with chronic kidney disease: the Atherosclerosis Risk in Communities study. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2014 , 34, 1770-7	9.4	40
473	ETC-1002 Lowers LDL-Cholesterol and is Well Tolerated in Hypercholesterolemic Patients Across Four Phase 2a Studies. <i>Journal of Clinical Lipidology</i> , 2014 , 8, 339-340	4.9	3
472	Fiber intake and plasminogen activator inhibitor-1 in type 2 diabetes: Look AHEAD (Action for Health in Diabetes) trial findings at baseline and year 1. <i>Journal of the Academy of Nutrition and Dietetics</i> , 2014 , 114, 1800-10.e2	3.9	6

471	Effects of fenofibric acid on carotid intima-media thickness in patients with mixed dyslipidemia on atorvastatin therapy: randomized, placebo-controlled study (FIRST). <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2014 , 34, 1298-306	9.4	55
470	Age- and sex-dependent upper reference limits for the high-sensitivity cardiac troponin T assay. <i>Journal of the American College of Cardiology</i> , 2014 , 63, 1441-8	15.1	226
469	Revascularization improves mortality in elderly patients with acute myocardial infarction complicated by cardiogenic shock. <i>International Journal of Cardiology</i> , 2014 , 172, 239-41	3.2	15
468	Loss-of-function mutations in APOC3, triglycerides, and coronary disease. <i>New England Journal of Medicine</i> , 2014 , 371, 22-31	59.2	721
467	Is high-intensity statin therapy associated with lower statin adherence compared with low- to moderate-intensity statin therapy? Implications of the 2013 American College of Cardiology/American Heart Association Cholesterol Management Guidelines. <i>Clinical Cardiology</i> , 2014 , 37, 653-9	3.3	48
466	Analysis of multiple association studies provides evidence of an expression QTL hub in gene-gene interaction network affecting HDL cholesterol levels. <i>PLoS ONE</i> , 2014 , 9, e92469	3.7	9
465	Low-density lipoprotein electronegativity is a novel cardiometabolic risk factor. <i>PLoS ONE</i> , 2014 , 9, e107340	3.7	21
464	Pharmacogenetic meta-analysis of genome-wide association studies of LDL cholesterol response to statins. <i>Nature Communications</i> , 2014 , 5, 5068	17.4	160
463	High-sensitivity cardiac troponin T and cognitive function and dementia risk: the atherosclerosis risk in communities study. <i>European Heart Journal</i> , 2014 , 35, 1817-24	9.5	28
462	Effects of the high-density lipoprotein mimetic agent CER-001 on coronary atherosclerosis in patients with acute coronary syndromes: a randomized trial. <i>European Heart Journal</i> , 2014 , 35, 3277-86	9.5	176
461	Reply from the authors. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2014 , 189, 869-70	10.2	
460	Comparative associations of diabetes risk factors with five measures of hyperglycemia. <i>BMJ Open Diabetes Research and Care</i> , 2014 , 2, e000002	4.5	12
459	Neck circumference is not associated with subclinical atherosclerosis in retired National Football League players. <i>Clinical Cardiology</i> , 2014 , 37, 402-7	3.3	15
458	Relation between playing position and coronary artery calcium scores in retired National Football League players. <i>American Journal of Cardiology</i> , 2014 , 114, 1836-40	3	10
457	Reply: Frequency of inappropriate and nonrecommended prasugrel prescription: great variations. <i>Journal of the American College of Cardiology</i> , 2014 , 64, 2434-5	15.1	
456	Dual role of the leukocyte integrin $\alpha 4 \beta 1$ in angiogenesis. <i>Journal of Immunology</i> , 2014 , 193, 4712-21	5.3	23
455	B-type natriuretic peptide and C-reactive protein in the prediction of atrial fibrillation risk: the CHARGE-AF Consortium of community-based cohort studies. <i>Europace</i> , 2014 , 16, 1426-33	3.9	112
454	Assessing risk prediction models using individual participant data from multiple studies. <i>American Journal of Epidemiology</i> , 2014 , 179, 621-32	3.8	36

453	Pre-morbid body mass index and mortality after incident heart failure: the ARIC Study. <i>Journal of the American College of Cardiology</i> , 2014 , 64, 2743-9	15.1	65
452	Essential role of CD11a in CD8+ T-cell accumulation and activation in adipose tissue. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2014 , 34, 34-43	9.4	36
451	Apolipoproteins do not add prognostic information beyond lipoprotein cholesterol measures among individuals with obesity and insulin resistance syndromes: the ARIC study. <i>European Journal of Preventive Cardiology</i> , 2014 , 21, 866-75	3.9	14
450	Distribution of calcification in carotid endarterectomy tissues: comparison of micro-computed tomography imaging with histology. <i>Vascular Medicine</i> , 2014 , 19, 343-50	3.3	7
449	Troponin T, NT-proBNP, and venous thromboembolism: the Longitudinal Investigation of Thromboembolism Etiology (LITE). <i>Vascular Medicine</i> , 2014 , 19, 33-41	3.3	13
448	Decrease the incentives to order lipid panels--reply. <i>JAMA Internal Medicine</i> , 2014 , 174, 473-4	11.5	
447	Efficacy, safety and effect on biomarkers related to cholesterol and lipoprotein metabolism of rosuvastatin 10 or 20 mg plus ezetimibe 10 mg vs. simvastatin 40 or 80 mg plus ezetimibe 10 mg in high-risk patients: Results of the GRAVITY randomized study. <i>Atherosclerosis</i> , 2014 , 232, 86-93	3.1	32
446	Icosapent Ethyl (eicosapentaenoic acid ethyl ester): Effects on Apolipoprotein C-III in Patients from the MARINE and ANCHOR Studies. <i>Journal of Clinical Lipidology</i> , 2014 , 8, 313-314	4.9	8
445	Rare LPL gene variants attenuate triglyceride reduction and HDL cholesterol increase in response to fenofibric acid therapy in individuals with mixed dyslipidemia. <i>Atherosclerosis</i> , 2014 , 234, 249-53	3.1	8
444	Three-year variability in plasma concentrations of the soluble receptor for advanced glycation end products (sRAGE). <i>Clinical Biochemistry</i> , 2014 , 47, 132-4	3.5	15
443	Attenuated adipose tissue and skeletal muscle inflammation in obese mice with combined CD4+ and CD8+ T cell deficiency. <i>Atherosclerosis</i> , 2014 , 233, 419-428	3.1	58
442	Frequency and practice-level variation in inappropriate and nonrecommended prasugrel prescribing: insights from the NCDR PINNACLE registry. <i>Journal of the American College of Cardiology</i> , 2014 , 63, 2876-7	15.1	41
441	The challenges of genome-wide interaction studies: lessons to learn from the analysis of HDL blood levels. <i>PLoS ONE</i> , 2014 , 9, e109290	3.7	12
440	Association of body mass index and waist circumference with subclinical atherosclerosis in retired NFL players. <i>Southern Medical Journal</i> , 2014 , 107, 633-9	0.6	13
439	Integration of Biomarkers with Plaque Imaging. <i>Contemporary Cardiology</i> , 2014 , 203-214	0.1	
438	Abstract P018: Calibration of Analytes Over Twenty-Five Years in the Atherosclerosis Risk in Communities Study. <i>Circulation</i> , 2014 , 129,	16.7	3
437	Chronic inflammation role in the obesity-diabetes association: a case-cohort study. <i>Diabetology and Metabolic Syndrome</i> , 2013 , 5, 31	5.6	58
436	Icosapent ethyl, a pure ethyl ester of eicosapentaenoic acid: effects on circulating markers of inflammation from the MARINE and ANCHOR studies. <i>American Journal of Cardiovascular Drugs</i> , 2013 , 13, 37-46	4	95

435	A novel mutation in the ABCA1 gene causing an atypical phenotype of Tangier disease. <i>Journal of Clinical Lipidology</i> , 2013 , 7, 82-7	4.9	20
434	Troponin T, B-type natriuretic peptide, C-reactive protein, and cause-specific mortality. <i>Annals of Epidemiology</i> , 2013 , 23, 66-73	6.4	59
433	The Effect of Lipid Modification on Peripheral Artery Disease after Endovascular Intervention Trial (ELIMIT). <i>Atherosclerosis</i> , 2013 , 231, 371-7	3.1	25
432	Comparison by meta-analysis of mortality after isolated coronary artery bypass grafting in women versus men. <i>American Journal of Cardiology</i> , 2013 , 112, 309-17	3	60
431	Association of gender with morbidity and mortality after isolated coronary artery bypass grafting. A propensity score matched analysis. <i>International Journal of Cardiology</i> , 2013 , 167, 180-4	3.2	41
430	Alteration of relation of atherogenic lipoprotein cholesterol to apolipoprotein B by intensive statin therapy in patients with acute coronary syndrome (from the Limiting UNDertreatment of lipids in ACS With Rosuvastatin [LUNAR] Trial). <i>American Journal of Cardiology</i> , 2013 , 111, 506-9	3	20
429	New therapeutic principles in dyslipidaemia: focus on LDL and Lp(a) lowering drugs. <i>European Heart Journal</i> , 2013 , 34, 1783-9	9.5	72
428	Coronary artery bypass graft surgery remains the standard of care for patients with diabetes. <i>Seminars in Thoracic and Cardiovascular Surgery</i> , 2013 , 25, 97-9	1.7	4
427	Patients with severe chronic kidney disease benefit from early revascularization after acute coronary syndrome. <i>International Journal of Cardiology</i> , 2013 , 168, 3741-6	3.2	35
426	Troponin T and N-terminal pro-B-type natriuretic peptide: a biomarker approach to predict heart failure risk—the atherosclerosis risk in communities study. <i>Clinical Chemistry</i> , 2013 , 59, 1802-10	5.5	69
425	Effects of icosapent ethyl on lipid and inflammatory parameters in patients with diabetes mellitus-2, residual elevated triglycerides (200-500 mg/dL), and on statin therapy at LDL-C goal: the ANCHOR study. <i>Cardiovascular Diabetology</i> , 2013 , 12, 100	8.7	51
424	Troponin T, N-terminal pro-B-type natriuretic peptide, and incidence of stroke: the atherosclerosis risk in communities study. <i>Stroke</i> , 2013 , 44, 961-7	6.7	120
423	Lipoprotein-associated phospholipase A2 and venous thromboembolism: a prospective study. <i>Thrombosis Research</i> , 2013 , 132, 44-6	8.2	2
422	Response to Zhou et al. Letter to the Editor: The effects of various intensities of physical activity and chronic inflammation in men and women by diabetes status in a national sample. <i>Diabetes Research and Clinical Practice</i> , 2013 , 99, e20	7.4	
421	Single nucleotide polymorphisms in cholesteryl ester transfer protein gene and recurrent coronary heart disease or mortality in patients with established atherosclerosis. <i>American Journal of Cardiology</i> , 2013 , 112, 1287-92	3	3
420	Effects of Icosapent Ethyl on Lipoprotein Particle Concentration and the Fatty Acid Desaturation Index in Statin-treated Patients With Persistent High Triglycerides (the ANCHOR Study). <i>Journal of Clinical Lipidology</i> , 2013 , 7, 270-271	4.9	3
419	Age, abdominal obesity, and baseline high-sensitivity C-reactive protein are associated with low-density lipoprotein cholesterol, non-high-density lipoprotein cholesterol, and apolipoprotein B responses to ezetimibe/simvastatin and atorvastatin in patients with metabolic syndrome. <i>Journal of Clinical Lipidology</i> , 2013 , 7, 292-303	4.9	13
418	Modest diet-induced weight loss reduces macrophage cholesterol efflux to plasma of patients with metabolic syndrome. <i>Journal of Clinical Lipidology</i> , 2013 , 7, 661-70	4.9	16

417	Application of speckle-tracking in the evaluation of carotid artery function in subjects with hypertension and diabetes. <i>Journal of the American Society of Echocardiography</i> , 2013 , 26, 901-909.e1	5.8	13
416	Association between statins and infections after coronary artery bypass grafting. <i>International Journal of Cardiology</i> , 2013 , 168, 117-20	3.2	16
415	Efficacy and safety of a novel dual modulator of adenosine triphosphate-citrate lyase and adenosine monophosphate-activated protein kinase in patients with hypercholesterolemia: results of a multicenter, randomized, double-blind, placebo-controlled, parallel-group trial. <i>Journal of the American College of Cardiology</i> , 2013 , 62, 1154-62	15.1	108
414	sRAGE and risk of diabetes, cardiovascular disease, and death. <i>Diabetes</i> , 2013 , 62, 2116-21	0.9	123
413	CD11a regulates effector CD8 T cell differentiation and central memory development in response to infection with <i>Listeria monocytogenes</i> . <i>Infection and Immunity</i> , 2013 , 81, 1140-51	3.7	35
412	Authors' reply. <i>American Journal of Cardiology</i> , 2013 , 111, 455-6	3	
411	Factors underlying regression of coronary atheroma with potent statin therapy. <i>European Heart Journal</i> , 2013 , 34, 1818-25	9.5	49
410	Cardiovascular biomarkers and subclinical brain disease in the atherosclerosis risk in communities study. <i>Stroke</i> , 2013 , 44, 1803-8	6.7	44
409	Coronary atheroma volume and cardiovascular events during maximally intensive statin therapy. <i>European Heart Journal</i> , 2013 , 34, 3182-90	9.5	69
408	Sleep apnea is associated with subclinical myocardial injury in the community. The ARIC-SHHS study. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2013 , 188, 1460-5	10.2	61
407	Rare APOA5 promoter variants associated with paradoxical HDL cholesterol decrease in response to fenofibric acid therapy. <i>Journal of Lipid Research</i> , 2013 , 54, 1980-7	6.3	7
406	Trans-ethnic fine-mapping of lipid loci identifies population-specific signals and allelic heterogeneity that increases the trait variance explained. <i>PLoS Genetics</i> , 2013 , 9, e1003379	6	94
405	Elevated high-sensitivity C-reactive protein as a risk marker of the attenuated relationship between serum cholesterol and cardiovascular events at older age. The ARIC Study. <i>American Journal of Epidemiology</i> , 2013 , 178, 1076-84	3.8	25
404	Association of genome-wide variation with highly sensitive cardiac troponin-T levels in European Americans and Blacks: a meta-analysis from atherosclerosis risk in communities and cardiovascular health studies. <i>Circulation: Cardiovascular Genetics</i> , 2013 , 6, 82-8		24
403	Combined association of creatinine, albuminuria, and cystatin C with all-cause mortality and cardiovascular and kidney outcomes. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2013 , 8, 434-42	6.9	32
402	Novel risk factors and the prediction of type 2 diabetes in the Atherosclerosis Risk in Communities (ARIC) study. <i>Diabetes Care</i> , 2013 , 36, 70-6	14.6	31
401	The association of plasma lactate with incident cardiovascular outcomes: the ARIC Study. <i>American Journal of Epidemiology</i> , 2013 , 178, 401-9	3.8	25
400	NH2-terminal pro-brain natriuretic peptide and risk of diabetes. <i>Diabetes</i> , 2013 , 62, 3189-93	0.9	75

399	Do genetic modifiers of high-density lipoprotein cholesterol and triglyceride levels also modify their response to a lifestyle intervention in the setting of obesity and type-2 diabetes mellitus?: The Action for Health in Diabetes (Look AHEAD) study. <i>Circulation: Cardiovascular Genetics</i> , 2013 , 6, 391-9		22
398	Lifestyle intervention and/or statins for the reduction of C-reactive protein in type 2 diabetes: from the look AHEAD study. <i>Obesity</i> , 2013 , 21, 944-50	8	42
397	Association between preoperative diuretic use and in-hospital outcomes after cardiac surgery. <i>Cardiovascular Therapeutics</i> , 2013 , 31, 291-7	3.3	6
396	Icosapent ethyl for the treatment of hypertriglyceridemia. <i>Expert Opinion on Pharmacotherapy</i> , 2013 , 14, 1409-16	4	13
395	Mendelian randomization studies do not support a causal role for reduced circulating adiponectin levels in insulin resistance and type 2 diabetes. <i>Diabetes</i> , 2013 , 62, 3589-98	0.9	95
394	APOE modulates the correlation between triglycerides, cholesterol, and CHD through pleiotropy, and gene-by-gene interactions. <i>Genetics</i> , 2013 , 195, 1397-405	4	18
393	Ceruloplasmin and heart failure in the Atherosclerosis Risk in Communities study. <i>Circulation: Heart Failure</i> , 2013 , 6, 936-43	7.6	32
392	C-reactive protein, but not low-density lipoprotein cholesterol levels, associate with coronary atheroma regression and cardiovascular events after maximally intensive statin therapy. <i>Circulation</i> , 2013 , 128, 2395-403	16.7	88
391	Intensive lifestyle modification reduces Lp-PLA2 in dyslipidemic HIV/HAART patients. <i>Medicine and Science in Sports and Exercise</i> , 2013 , 45, 1043-50	1.2	17
390	Correlates of repeat lipid testing in patients with coronary heart disease. <i>JAMA Internal Medicine</i> , 2013 , 173, 1439-44	11.5	15
389	Retinol binding protein 4 and incident diabetes--the Atherosclerosis Risk in Communities Study (ARIC Study). <i>Revista Brasileira De Epidemiologia</i> , 2013 , 16, 388-97	1.3	13
388	Lactate and risk of incident diabetes in a case-cohort of the atherosclerosis risk in communities (ARIC) study. <i>PLoS ONE</i> , 2013 , 8, e55113	3.7	38
387	Elevated plasma SPARC levels are associated with insulin resistance, dyslipidemia, and inflammation in gestational diabetes mellitus. <i>PLoS ONE</i> , 2013 , 8, e81615	3.7	32
386	The impact of rapid weight loss on oxidative stress markers and the expression of the metabolic syndrome in obese individuals. <i>Journal of Obesity</i> , 2013 , 2013, 729515	3.7	28
385	Novel markers of kidney function as predictors of ESRD, cardiovascular disease, and mortality in the general population. <i>American Journal of Kidney Diseases</i> , 2012 , 59, 653-62	7.4	134
384	Chromosome 9p21 single nucleotide polymorphisms are not associated with recurrent myocardial infarction in patients with established coronary artery disease. <i>Circulation Journal</i> , 2012 , 76, 950-6	2.9	23
383	Combined association of albuminuria and cystatin C-based estimated GFR with mortality, coronary heart disease, and heart failure outcomes: the Atherosclerosis Risk in Communities (ARIC) Study. <i>American Journal of Kidney Diseases</i> , 2012 , 60, 207-16	7.4	63
382	Effects of dalcetrapib in patients with a recent acute coronary syndrome. <i>New England Journal of Medicine</i> , 2012 , 367, 2089-99	59.2	1424

381	Study design, rationale, and baseline characteristics: evaluation of fenofibric acid on carotid intima-media thickness in patients with type IIb dyslipidemia with residual risk in addition to atorvastatin therapy (FIRST) trial. <i>Cardiovascular Drugs and Therapy</i> , 2012 , 26, 349-58	3.9	13
380	The 9p21 genetic variant is additive to carotid intima media thickness and plaque in improving coronary heart disease risk prediction in white participants of the Atherosclerosis Risk in Communities (ARIC) Study. <i>Atherosclerosis</i> , 2012 , 222, 135-7	3.1	11
379	Association between traditional cholesterol parameters, lipoprotein particle concentration, novel biomarkers and carotid plaques in retired National Football League players. <i>Atherosclerosis</i> , 2012 , 222, 551-6	3.1	15
378	A genetic risk score based on direct associations with coronary heart disease improves coronary heart disease risk prediction in the Atherosclerosis Risk in Communities (ARIC), but not in the Rotterdam and Framingham Offspring, Studies. <i>Atherosclerosis</i> , 2012 , 223, 421-6	3.1	51
377	ApoE and the role of very low density lipoproteins in adipose tissue inflammation. <i>Atherosclerosis</i> , 2012 , 223, 342-9	3.1	20
376	Non-high-density lipoprotein cholesterol calculation and goal awareness among physicians-in-training. <i>Journal of Clinical Lipidology</i> , 2012 , 6, 50-7	4.9	14
375	Effects of coadministered extended-release niacin/laropirant and simvastatin on lipoprotein subclasses in patients with dyslipidemia. <i>Journal of Clinical Lipidology</i> , 2012 , 6, 235-43	4.9	8
374	Clinical use of genetic typing in human lipid disorders. <i>Journal of Clinical Lipidology</i> , 2012 , 6, 199-207	4.9	3
373	Non-high-density lipoprotein cholesterol reporting and goal attainment in primary care. <i>Journal of Clinical Lipidology</i> , 2012 , 6, 545-52	4.9	9
372	Icosapent ethyl, a pure EPA omega-3 fatty acid: effects on lipoprotein particle concentration and size in patients with very high triglyceride levels (the MARINE study). <i>Journal of Clinical Lipidology</i> , 2012 , 6, 565-72	4.9	68
371	Developing and assessing cardiovascular biomarkers. <i>Translational Research</i> , 2012 , 159, 265-76	11	19
370	Effect of dalcetrapib plus pravastatin on lipoprotein metabolism and high-density lipoprotein composition and function in dyslipidemic patients: results of a phase IIb dose-ranging study. <i>American Heart Journal</i> , 2012 , 163, 515-21, 521.e1-3	4.9	45
369	Changes in prescription patterns before and after reporting of the Ezetimibe and Simvastatin in Hypercholesterolemia Enhances Atherosclerosis Regression trial (ENHANCE) results and expected effects on low-density lipoprotein-cholesterol reduction. <i>Journal of Clinical Lipidology</i> , 2012 , 6, 180-91	4.9	16
368	The effect of various intensities of physical activity and chronic inflammation in men and women by diabetes status in a national sample. <i>Diabetes Research and Clinical Practice</i> , 2012 , 97, e6-8	7.4	18
367	Chronic hyperglycemia and subclinical myocardial injury. <i>Journal of the American College of Cardiology</i> , 2012 , 59, 484-9	15.1	93
366	Large-scale gene-centric meta-analysis across 32 studies identifies multiple lipid loci. <i>American Journal of Human Genetics</i> , 2012 , 91, 823-38	11	189
365	Outcomes of preoperative angiotensin-converting enzyme inhibitor therapy in patients undergoing isolated coronary artery bypass grafting. <i>American Journal of Cardiology</i> , 2012 , 110, 919-23	3	34
364	Efficacy and safety of eicosapentaenoic acid ethyl ester (AMR101) therapy in statin-treated patients with persistent high triglycerides (from the ANCHOR study). <i>American Journal of Cardiology</i> , 2012 , 110, 984-92	3	243

363	Lifestyle Modification with Diet and Exercise in Obese Patients with Heart Failure - A Pilot Study. <i>Journal of Obesity & Weight Loss Therapy</i> , 2012 , 2, 1-8	0	17
362	Prediction of incident heart failure in general practice: the Atherosclerosis Risk in Communities (ARIC) Study. <i>Circulation: Heart Failure</i> , 2012 , 5, 422-9	7.6	128
361	ApoA-I induction as a potential cardioprotective strategy: rationale for the SUSTAIN and ASSURE studies. <i>Cardiovascular Drugs and Therapy</i> , 2012 , 26, 181-7	3.9	67
360	Genome-wide association study evaluating lipoprotein-associated phospholipase A2 mass and activity at baseline and after rosuvastatin therapy. <i>Circulation: Cardiovascular Genetics</i> , 2012 , 5, 676-85		30
359	Response to Letter From Watanabe and Aizawa Regarding Article, Blood Lipid Levels, Lipid-Lowering Medications, and the Incidence of Atrial Fibrillation: The Atherosclerosis Risk in Communities (ARIC) Study, by Lopez et al. <i>Circulation: Arrhythmia and Electrophysiology</i> , 2012 , 5,	6.4	1
358	Novel loci for adiponectin levels and their influence on type 2 diabetes and metabolic traits: a multi-ethnic meta-analysis of 45,891 individuals. <i>PLoS Genetics</i> , 2012 , 8, e1002607	6	326
357	Associations between lipoprotein(a) levels and cardiovascular outcomes in black and white subjects: the Atherosclerosis Risk in Communities (ARIC) Study. <i>Circulation</i> , 2012 , 125, 241-9	16.7	178
356	LPL gene variants affect apoC-III response to combination therapy of statins and fenofibric acid in a randomized clinical trial of individuals with mixed dyslipidemia. <i>Journal of Lipid Research</i> , 2012 , 53, 556-560	6.3	11
355	Adiponectin and the mediation of HDL-cholesterol change with improved lifestyle: the Look AHEAD Study. <i>Journal of Lipid Research</i> , 2012 , 53, 2726-33	6.3	30
354	Interaction between SNPs in the RXRA and near ANGPTL3 gene region inhibits apoB reduction after statin-fenofibric acid therapy in individuals with mixed dyslipidemia. <i>Journal of Lipid Research</i> , 2012 , 53, 2425-8	6.3	11
353	Carotid arterial wall characteristics are associated with incident ischemic stroke but not coronary heart disease in the Atherosclerosis Risk in Communities (ARIC) study. <i>Stroke</i> , 2012 , 43, 103-8	6.7	92
352	Lipid-related markers and cardiovascular disease prediction. <i>JAMA - Journal of the American Medical Association</i> , 2012 , 307, 2499-506	27.4	271
351	Eight genetic loci associated with variation in lipoprotein-associated phospholipase A2 mass and activity and coronary heart disease: meta-analysis of genome-wide association studies from five community-based studies. <i>European Heart Journal</i> , 2012 , 33, 238-51	9.5	75
350	Common carotid artery intima-media thickness is as good as carotid intima-media thickness of all carotid artery segments in improving prediction of coronary heart disease risk in the Atherosclerosis Risk in Communities (ARIC) study. <i>European Heart Journal</i> , 2012 , 33, 183-90	9.5	118
349	Blood lipid levels, lipid-lowering medications, and the incidence of atrial fibrillation: the atherosclerosis risk in communities study. <i>Circulation: Arrhythmia and Electrophysiology</i> , 2012 , 5, 155-62	6.4	86
348	Relation of lipid gene scores to longitudinal trends in lipid levels and incidence of abnormal lipid levels among individuals of European ancestry: the Atherosclerosis Risk in Communities (ARIC) study. <i>Circulation: Cardiovascular Genetics</i> , 2012 , 5, 73-80		27
347	Racial differences in association of elevated interleukin-18 levels with type 2 diabetes: the Atherosclerosis Risk in Communities study. <i>Diabetes Care</i> , 2012 , 35, 1513-8	14.6	11
346	Association of apolipoprotein A1 and B with kidney function and chronic kidney disease in two multiethnic population samples. <i>Nephrology Dialysis Transplantation</i> , 2012 , 27, 2839-47	4.3	26

345	Programmable bio-nanochip technology for the diagnosis of cardiovascular disease at the point-of-care. <i>Methodist DeBakey Cardiovascular Journal</i> , 2012 , 8, 6-12	2.1	33
344	Multi-ethnic analysis of lipid-associated loci: the NHLBI CARE project. <i>PLoS ONE</i> , 2012 , 7, e36473	3.7	39
343	Gene-centric meta-analysis of lipid traits in African, East Asian and Hispanic populations. <i>PLoS ONE</i> , 2012 , 7, e50198	3.7	37
342	Diabetes medication use and blood lactate level among participants with type 2 diabetes: the atherosclerosis risk in communities carotid MRI study. <i>PLoS ONE</i> , 2012 , 7, e51237	3.7	11
341	Segmental analysis of carotid arterial strain using speckle-tracking. <i>Journal of the American Society of Echocardiography</i> , 2011 , 24, 1276-1284.e5	5.8	25
340	Real-time co-registration using novel ultrasound technology: ex vivo validation and in vivo applications. <i>Journal of the American Society of Echocardiography</i> , 2011 , 24, 720-8	5.8	12
339	Efficacy and safety of a novel oral inducer of apolipoprotein a-I synthesis in statin-treated patients with stable coronary artery disease a randomized controlled trial. <i>Journal of the American College of Cardiology</i> , 2011 , 57, 1111-9	15.1	138
338	Familial hypercholesterolemia: screening, diagnosis and management of pediatric and adult patients: clinical guidance from the National Lipid Association Expert Panel on Familial Hypercholesterolemia. <i>Journal of Clinical Lipidology</i> , 2011 , 5, 133-140	4.9	181
337	Familial hypercholesterolemias: prevalence, genetics, diagnosis and screening recommendations from the National Lipid Association Expert Panel on Familial Hypercholesterolemia. <i>Journal of Clinical Lipidology</i> , 2011 , 5, S9-17	4.9	228
336	Familial hypercholesterolemia: screening, diagnosis and management of pediatric and adult patients: clinical guidance from the National Lipid Association Expert Panel on Familial Hypercholesterolemia. <i>Journal of Clinical Lipidology</i> , 2011 , 5, S1-8	4.9	329
335	Achievement of specified low-density lipoprotein cholesterol, non-high-density lipoprotein cholesterol apolipoprotein B, and high-sensitivity C-reactive protein levels with ezetimibe/simvastatin or atorvastatin in metabolic syndrome patients with and without atherosclerotic vascular disease (from the YMET study). <i>Journal of Clinical Lipidology</i> , 2011 , 5, 474-82	4.9	17
334	Effects of combination therapy with rosuvastatin and fenofibric acid in patients with mixed dyslipidemia and high-sensitivity C-reactive protein (\geq mg/L). cmb@bcm.tmc.edu. <i>Journal of Clinical Lipidology</i> , 2011 , 5, 401-7	4.9	3
333	Clinical utility of inflammatory markers and advanced lipoprotein testing: advice from an expert panel of lipid specialists. <i>Journal of Clinical Lipidology</i> , 2011 , 5, 338-67	4.9	201
332	Pharmacological strategies for lowering LDL cholesterol: statins and beyond. <i>Nature Reviews Cardiology</i> , 2011 , 8, 253-65	14.8	75
331	Effect of two intensive statin regimens on progression of coronary disease. <i>New England Journal of Medicine</i> , 2011 , 365, 2078-87	59.2	574
330	Peripheral artery disease, biomarkers, and darapladib. <i>American Heart Journal</i> , 2011 , 161, 972-8	4.9	15
329	Institutional, provider, and patient correlates of low-density lipoprotein and non-high-density lipoprotein cholesterol goal attainment according to the Adult Treatment Panel III guidelines. <i>American Heart Journal</i> , 2011 , 161, 1140-6	4.9	38
328	Frequency and correlates of treatment intensification for elevated cholesterol levels in patients with cardiovascular disease. <i>American Heart Journal</i> , 2011 , 162, 725-732.e1	4.9	41

327	Barriers to non-HDL cholesterol goal attainment by providers. <i>American Journal of Medicine</i> , 2011 , 124, 876-80.e2	2.4	28
326	White blood cell count, C-reactive protein, and incident heart failure in the Atherosclerosis Risk in Communities (ARIC) Study. <i>Annals of Epidemiology</i> , 2011 , 21, 739-48	6.4	43
325	Variability and persistence of aspirin response in lower extremity peripheral arterial disease patients. <i>Journal of Vascular Surgery</i> , 2011 , 53, 668-75	3.5	16
324	Impact of statins on progression of atherosclerosis: rationale and design of SATURN (Study of Coronary Atheroma by InTravascular Ultrasound: effect of Rosuvastatin versus Atorvastatin). <i>Current Medical Research and Opinion</i> , 2011 , 27, 1119-29	2.5	37
323	Differential effect of weight loss with low-fat diet or high-fat diet restriction on inflammation in the liver and adipose tissue of mice with diet-induced obesity. <i>Atherosclerosis</i> , 2011 , 219, 100-8	3.1	26
322	Relation of cholesterol and lipoprotein parameters with carotid artery plaque characteristics: the Atherosclerosis Risk in Communities (ARIC) carotid MRI study. <i>Atherosclerosis</i> , 2011 , 219, 596-602	3.1	30
321	Variants in the APOA5 gene region and the response to combination therapy with statins and fenofibric acid in a randomized clinical trial of individuals with mixed dyslipidemia. <i>Atherosclerosis</i> , 2011 , 219, 737-42	3.1	33
320	Safety and efficacy of dalcetrapib on atherosclerotic disease using novel non-invasive multimodality imaging (dal-PLAQUE): a randomised clinical trial. <i>Lancet, The</i> , 2011 , 378, 1547-59	4.0	407
319	Genetic determinants of plasma von Willebrand factor antigen levels: a target gene SNP and haplotype analysis of ARIC cohort. <i>Blood</i> , 2011 , 117, 5224-30	2.2	38
318	Isolated coronary artery bypass grafting in obese individuals: a propensity matched analysis of outcomes. <i>Circulation Journal</i> , 2011 , 75, 1378-85	2.9	20
317	Effect of the cannabinoid receptor-1 antagonist rimonabant on inflammation in mice with diet-induced obesity. <i>Obesity</i> , 2011 , 19, 505-13	8	17
316	Automatic quantification of muscle volumes in magnetic resonance imaging scans of the lower extremities. <i>Magnetic Resonance Imaging</i> , 2011 , 29, 1065-75	3.3	23
315	The editor's roundtable: JUPITER follow-up. <i>American Journal of Cardiology</i> , 2011 , 107, 1549-57	3	2
314	Usefulness of single nucleotide polymorphism in chromosome 4q25 to predict in-hospital and long-term development of atrial fibrillation and survival in patients undergoing coronary artery bypass grafting. <i>American Journal of Cardiology</i> , 2011 , 107, 1504-9	3	32
313	Eicosapentaenoic acid ethyl ester (AMR101) therapy in patients with very high triglyceride levels (from the Multi-center, placebo-controlled, Randomized, double-blinded, 12-week study with an open-label Extension [MARINE] trial). <i>American Journal of Cardiology</i> , 2011 , 108, 682-90	3	254
312	Intramural coronary lipid injection induces atheromatous lesions expressing proinflammatory chemokines: implications for the development of a porcine model of atherosclerosis. <i>Cardiovascular Revascularization Medicine</i> , 2011 , 12, 304-11	1.6	9
311	Long-term efficacy of adding fenofibric acid to moderate-dose statin therapy in patients with persistent elevated triglycerides. <i>Cardiovascular Drugs and Therapy</i> , 2011 , 25, 59-67	3.9	14
310	Simultaneous bilateral magnetic resonance imaging of the femoral arteries in peripheral arterial disease patients. <i>Journal of Magnetic Resonance Imaging</i> , 2011 , 34, 150-6	5.6	5

309	Meta-analysis of genome-wide association studies in >80 000 subjects identifies multiple loci for C-reactive protein levels. <i>Circulation</i> , 2011 , 123, 731-8	16.7	395
308	Triglycerides and cardiovascular disease: a scientific statement from the American Heart Association. <i>Circulation</i> , 2011 , 123, 2292-333	16.7	1222
307	Combination of niacin and fenofibrate with lifestyle changes improves dyslipidemia and hypoadiponectinemia in HIV patients on antiretroviral therapy: results of "heart positive," a randomized, controlled trial. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2011 , 96, 2236-47	5.6	51
306	Nontraditional markers of glycemia: associations with microvascular conditions. <i>Diabetes Care</i> , 2011 , 34, 960-7	14.6	91
305	CD11c controls herpes simplex virus 1 responses to limit virus replication during primary infection. <i>Journal of Virology</i> , 2011 , 85, 9945-55	6.6	16
304	Association of variation at the ABO locus with circulating levels of soluble intercellular adhesion molecule-1, soluble P-selectin, and soluble E-selectin: a meta-analysis. <i>Circulation: Cardiovascular Genetics</i> , 2011 , 4, 681-6		59
303	Cardiac troponin T measured by a highly sensitive assay predicts coronary heart disease, heart failure, and mortality in the Atherosclerosis Risk in Communities Study. <i>Circulation</i> , 2011 , 123, 1367-76	16.7	540
302	CD11c/CD18 expression is upregulated on blood monocytes during hypertriglyceridemia and enhances adhesion to vascular cell adhesion molecule-1. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2011 , 31, 160-6	9.4	121
301	Nutrition and metabolism--sphingolipids and branched chain amino acids: indicators and effectors of adipose tissue function and diabetes risk. <i>Current Opinion in Lipidology</i> , 2011 , 22, 503-4	4.4	3
300	Relationship between circulating levels of RANTES (regulated on activation, normal T-cell expressed, and secreted) and carotid plaque characteristics: the Atherosclerosis Risk in Communities (ARIC) Carotid MRI Study. <i>European Heart Journal</i> , 2011 , 32, 459-68	9.5	43
299	Metabolic factors, adipose tissue, and plasminogen activator inhibitor-1 levels in type 2 diabetes: findings from the look AHEAD study. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2011 , 31, 1689-95	9.4	43
298	Sources of variability in measurements of cardiac troponin T in a community-based sample: the atherosclerosis risk in communities study. <i>Clinical Chemistry</i> , 2011 , 57, 891-7	5.5	68
297	Meta-analysis of genome-wide association studies from the CHARGE consortium identifies common variants associated with carotid intima media thickness and plaque. <i>Nature Genetics</i> , 2011 , 43, 940-7	36.3	168
296	Racial differences in glycemic markers: a cross-sectional analysis of community-based data. <i>Annals of Internal Medicine</i> , 2011 , 154, 303-9	8	147
295	Rust and Rupture: Atherosclerosis 2011 , 89-97		
294	Biological, clinical and population relevance of 95 loci for blood lipids. <i>Nature</i> , 2010 , 466, 707-13	50.4	2742
293	A 1-year lifestyle intervention for weight loss in individuals with type 2 diabetes reduces high C-reactive protein levels and identifies metabolic predictors of change: from the Look AHEAD (Action for Health in Diabetes) study. <i>Diabetes Care</i> , 2010 , 33, 2297-303	14.6	72
292	Large-scale genomic studies reveal central role of ABO in sP-selectin and sICAM-1 levels. <i>Human Molecular Genetics</i> , 2010 , 19, 1863-72	5.6	186

291	CD11c expression in adipose tissue and blood and its role in diet-induced obesity. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2010 , 30, 186-92	9.4	111
290	Association of blood lactate with type 2 diabetes: the Atherosclerosis Risk in Communities Carotid MRI Study. <i>International Journal of Epidemiology</i> , 2010 , 39, 1647-55	7.8	133
289	Carotid atherosclerosis progression in familial hypercholesterolemia patients: a pooled analysis of the ASAP, ENHANCE, RADIANCE 1, and CAPTIVATE studies. <i>Circulation: Cardiovascular Imaging</i> , 2010 , 3, 398-404	3.9	18
288	Marine omega-3 fatty acid intake: associations with cardiometabolic risk and response to weight loss intervention in the Look AHEAD (Action for Health in Diabetes) study. <i>Diabetes Care</i> , 2010 , 33, 197-9	14.6	20
287	Association of circulating matrix metalloproteinases with carotid artery characteristics: the Atherosclerosis Risk in Communities Carotid MRI Study. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2010 , 30, 1034-42	9.4	30
286	Effect of niacin ER/lovastatin on claudication symptoms in patients with peripheral artery disease. <i>Vascular Medicine</i> , 2010 , 15, 171-9	3.3	28
285	METEOR Trial Reports on the Effect of Rosuvastatin on Progression of Carotid Intima-Media Thickness in Low-Risk Individuals with Subclinical Atherosclerosis. <i>Physician and Sportsmedicine</i> , 2010 , 38, 180-2	2.4	2
284	Intercellular adhesion molecule-1 G241R polymorphism predicts risk of incident ischemic stroke: Atherosclerosis Risk in Communities study. <i>Stroke</i> , 2010 , 41, 1038-40	6.7	15
283	High-molecular-weight adiponectin and the risk of type 2 diabetes in the ARIC study. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2010 , 95, 5097-104	5.6	81
282	Carotid intima-media thickness and presence or absence of plaque improves prediction of coronary heart disease risk: the ARIC (Atherosclerosis Risk in Communities) study. <i>Journal of the American College of Cardiology</i> , 2010 , 55, 1600-7	15.1	650
281	Safety of extended-release niacin/laropiprant in patients with dyslipidemia. <i>Journal of Clinical Lipidology</i> , 2010 , 4, 105-112.e1	4.9	25
280	Management of Lp(a). <i>Journal of Clinical Lipidology</i> , 2010 , 4, 240-7	4.9	46
279	Insights from recent meta-analysis: role of high-density lipoprotein cholesterol in reducing cardiovascular events and rates of atherosclerotic disease progression. <i>Journal of Clinical Lipidology</i> , 2010 , 4, 365-70	4.9	14
278	Preoperative statin therapy decreases risk of postoperative renal insufficiency. <i>Cardiovascular Therapeutics</i> , 2010 , 28, 80-6	3.3	35
277	Lipoprotein-associated phospholipase A(2) and risk of coronary disease, stroke, and mortality: collaborative analysis of 32 prospective studies. <i>Lancet, The</i> , 2010 , 375, 1536-44	40	469
276	Duffy antigen receptor for chemokines (Darc) polymorphism regulates circulating concentrations of monocyte chemoattractant protein-1 and other inflammatory mediators. <i>Blood</i> , 2010 , 115, 5289-99	2.2	96
275	Variation in the checkpoint kinase 2 gene is associated with type 2 diabetes in multiple populations. <i>Acta Diabetologica</i> , 2010 , 47 Suppl 1, 199-207	3.9	4
274	Baseline lipoprotein lipids and low-density lipoprotein cholesterol response to prescription omega-3 acid ethyl ester added to Simvastatin therapy. <i>American Journal of Cardiology</i> , 2010 , 105, 1409-12	3	22

273	The transcription factor 7-like 2 (TCF7L2) polymorphism may be associated with focal arteriolar narrowing in Caucasians with hypertension or without diabetes: the ARIC Study. <i>BMC Endocrine Disorders</i> , 2010 , 10, 9	3.3	7
272	Impact of adventitial neovascularisation on atherosclerotic plaque composition and vascular remodelling in a porcine model of coronary atherosclerosis. <i>EuroIntervention</i> , 2010 , 5, 981-988	3.1	9
271	Genetic Determinants of Plasma Von Willebrand Factor Antigen Levels: A Target Gene SNP and Haplotype Analysis of the ARIC Cohort. <i>Blood</i> , 2010 , 116, 4310-4310	2.2	
270	Coronary heart disease risk, aspirin use, and apolipoprotein(a) 4399Met allele in the Atherosclerosis Risk in Communities (ARIC) study. <i>Thrombosis and Haemostasis</i> , 2009 , 102, 179-80	7	10
269	Advances in lipid testing and management in patients with diabetes mellitus. <i>Endocrine Practice</i> , 2009 , 15, 641-52	3.2	3
268	"Risky business": ten years is not a lifetime. <i>Circulation</i> , 2009 , 119, 362-4	16.7	13
267	ACCF/AHA/ACP 2009 competence and training statement: a curriculum on prevention of cardiovascular disease: a report of the American College of Cardiology Foundation/American Heart Association/American College of Physicians Task Force on Competence and Training (Writing Committee to Develop a Competence and Training Statement on Prevention of Cardiovascular	16.7	21
266	Inflammation, adipose tissue, and T cells: what is the "straight skinny" on lean versus fat mice?. <i>Circulation Research</i> , 2009 , 105, e3-4; author reply e5; <i>Circulation</i> , 2009 , 120, e100-26	15.7	
265	Longitudinal impact of physical activity on lipid profiles in middle-aged adults: the Atherosclerosis Risk in Communities Study. <i>Journal of Lipid Research</i> , 2009 , 50, 1685-91	6.3	63
264	Functional role of CD11c+ monocytes in atherogenesis associated with hypercholesterolemia. <i>Circulation</i> , 2009 , 119, 2708-17	16.7	172
263	Lipoprotein-associated phospholipase A2 and high-sensitivity C-reactive protein improve the stratification of ischemic stroke risk in the Atherosclerosis Risk in Communities (ARIC) study. <i>Stroke</i> , 2009 , 40, 376-81	6.7	68
262	Screening for kidney disease in vascular patients: SCreening for Occult RENal Disease (SCORED) experience. <i>Nephrology Dialysis Transplantation</i> , 2009 , 24, 2452-7	4.3	17
261	Inflammatory protein levels and depression screening after coronary stenting predict major adverse coronary events. <i>Biological Research for Nursing</i> , 2009 , 11, 163-73	2.6	7
260	Criteria for evaluation of novel markers of cardiovascular risk: a scientific statement from the American Heart Association. <i>Circulation</i> , 2009 , 119, 2408-16	16.7	834
259	National Academy of Clinical Biochemistry Laboratory Medicine Practice guidelines: emerging biomarkers for primary prevention of cardiovascular disease. <i>Clinical Chemistry</i> , 2009 , 55, 378-84	5.5	324
258	Impact of adding a single allele in the 9p21 locus to traditional risk factors on reclassification of coronary heart disease risk and implications for lipid-modifying therapy in the Atherosclerosis Risk in Communities study. <i>Circulation: Cardiovascular Genetics</i> , 2009 , 2, 279-85		77
257	Statin-induced diabetes: will it change clinical practice?. <i>Diabetes Care</i> , 2009 , 32, 1941-3	14.6	8
256	Correlates of carotid plaque presence and composition as measured by MRI: the Atherosclerosis Risk in Communities Study. <i>Circulation: Cardiovascular Imaging</i> , 2009 , 2, 314-22	3.9	49

255	The 9p21 susceptibility locus for coronary artery disease and the severity of coronary atherosclerosis. <i>BMC Cardiovascular Disorders</i> , 2009 , 9, 3	2.3	31
254	Pooled analyses of effects on C-reactive protein and low density lipoprotein cholesterol in placebo-controlled trials of ezetimibe monotherapy or ezetimibe added to baseline statin therapy. <i>American Journal of Cardiology</i> , 2009 , 103, 369-74	3	72
253	Efficacy and safety of ABT-335 (fenofibric acid) in combination with atorvastatin in patients with mixed dyslipidemia. <i>American Journal of Cardiology</i> , 2009 , 103, 515-22	3	54
252	Lipid-altering efficacy and safety of ezetimibe/simvastatin versus atorvastatin in patients with hypercholesterolemia and the metabolic syndrome (from the VYMET study). <i>American Journal of Cardiology</i> , 2009 , 103, 1694-702	3	55
251	Improved Horvitz-Thompson Estimation of Model Parameters from Two-phase Stratified Samples: Applications in Epidemiology. <i>Statistics in Biosciences</i> , 2009 , 1, 32	1.5	86
250	Candidate genetic analysis of plasma high-density lipoprotein-cholesterol and severity of coronary atherosclerosis. <i>BMC Medical Genetics</i> , 2009 , 10, 111	2.1	37
249	Rationale and design of the dal-OUTCOMES trial: efficacy and safety of dalcetrapib in patients with recent acute coronary syndrome. <i>American Heart Journal</i> , 2009 , 158, 896-901.e3	4.9	166
248	ACCF/AHA/ACP 2009 competence and training statement: a curriculum on prevention of cardiovascular disease: a report of the American College of Cardiology Foundation/American Heart Association/American College of Physicians Task Force on Competence and Training (Writing Committee on Competence and Training Statement on Prevention of Cardiovascular Disease)	15.1	44
247	Clinical implications of JUPITER (Justification for the Use of statins in Prevention: an Intervention Trial Evaluating Rosuvastatin) in a U.S. population insights from the ARIC (Atherosclerosis Risk in Communities) study. <i>Journal of the American College of Cardiology</i> , 2009 , 54, 2388-95	15.1	40
246	Effects of prescription omega-3-acid ethyl esters on lipoprotein particle concentrations, apolipoproteins AI and CIII, and lipoprotein-associated phospholipase A(2) mass in statin-treated subjects with hypertriglyceridemia. <i>Journal of Clinical Lipidology</i> , 2009 , 3, 332-40	4.9	60
245	Efficacy and tolerability of multidrug therapy for hypertriglyceridemia. <i>Journal of Clinical Lipidology</i> , 2009 , 3, 341-4	4.9	2
244	Transcription factor 7-like 2 (TCF7L2) polymorphism and context-specific risk of type 2 diabetes in African American and Caucasian adults: the Atherosclerosis Risk in Communities study. <i>Diabetes</i> , 2009 , 58, 285-9	0.9	23
243	Differences in responses of platelets to fluid shear stress in patients with peripheral artery disease (PAD) and coronary artery disease (CAD). <i>Platelets</i> , 2009 , 20, 199-205	3.6	10
242	Low-density lipoprotein cholesterol reduction and goal achievement with ezetimibe/simvastatin versus atorvastatin or rosuvastatin in patients with diabetes, metabolic syndrome, or neither disease, stratified by National Cholesterol Education Program risk category. <i>Metabolic Syndrome and Related Disorders</i> , 2009 , 7, 601-10	2.6	8
241	Using the whole cohort in the analysis of case-cohort data. <i>American Journal of Epidemiology</i> , 2009 , 169, 1398-405	3.8	102
240	Development and validation of a patient self-assessment score for diabetes risk. <i>Annals of Internal Medicine</i> , 2009 , 151, 775-83	8	180
239	What's the deal with niacin development: is laropirant add-on therapy a winning strategy to beat a straight flush?. <i>Current Opinion in Lipidology</i> , 2009 , 20, 467-76	4.4	28
238	Obesity: an independent predictor of in-hospital postoperative renal insufficiency among patients undergoing cardiac surgery?. <i>Texas Heart Institute Journal</i> , 2009 , 36, 540-5	0.8	15

237 Emerging Assays **2009**, 178-183

236	Monocyte integrin CD11c/CD18 is a functional biomarker for risk of cardiovascular disease. <i>FASEB Journal</i> , 2009 , 23, 593.7	0.9	
235	Monocyte CD11c/CD18 expression is upregulated postprandially and mediates firm arrest on VCAM-1. <i>FASEB Journal</i> , 2009 , 23, 640.5	0.9	
234	Increased myocardial susceptibility to repetitive ischemia with high-fat diet-induced obesity. <i>Obesity</i> , 2008 , 16, 2593-600	8	28
233	How to identify patients with vulnerable plaques. <i>Diabetes, Obesity and Metabolism</i> , 2008 , 10, 824-33	6.7	5
232	Association of C-reactive protein and microalbuminuria (from the National Health and Nutrition Examination Surveys, 1999 to 2004). <i>American Journal of Cardiology</i> , 2008 , 101, 401-6	3	67
231	Efficacy and tolerability of fluvastatin XL 80 mg alone, ezetimibe alone, and the combination of fluvastatin XL 80 mg with ezetimibe in patients with a history of muscle-related side effects with other statins. <i>American Journal of Cardiology</i> , 2008 , 101, 490-6	3	76
230	Effects of laropirant on nicotinic acid-induced flushing in patients with dyslipidemia. <i>American Journal of Cardiology</i> , 2008 , 101, 625-30	3	152
229	The editor's roundtable: atherosclerosis regression. <i>American Journal of Cardiology</i> , 2008 , 101, 967-74	3	6
228	Comparison of the safety and efficacy of a combination tablet of niacin extended release and simvastatin vs simvastatin monotherapy in patients with increased non-HDL cholesterol (from the SEACOAST I study). <i>American Journal of Cardiology</i> , 2008 , 101, 1428-36	3	78
227	The editor's roundtable: lipid management beyond statins-reducing residual cardiovascular risk. <i>American Journal of Cardiology</i> , 2008 , 102, 559-67	3	7
226	Does preoperative statin therapy improve outcomes in patients undergoing isolated cardiac valve surgery?. <i>American Journal of Cardiology</i> , 2008 , 102, 1235-9	3	23
225	The effect of darapladib on plasma lipoprotein-associated phospholipase A2 activity and cardiovascular biomarkers in patients with stable coronary heart disease or coronary heart disease risk equivalent: the results of a multicenter, randomized, double-blind, placebo-controlled study. <i>Journal of the American College of Cardiology</i> , 2008 , 51, 1432-41	15.1	177
224	Statin therapy alters the relationship between apolipoprotein B and low-density lipoprotein cholesterol and non-high-density lipoprotein cholesterol targets in high-risk patients: the MERCURY II (Measuring Effective Reductions in Cholesterol Using Rosuvastatin) trial. <i>Journal of the American College of Cardiology</i> , 2008 , 52, 624-32	15.1	83
223	A case report of myopathy from consumption of red yeast rice. <i>Journal of Clinical Lipidology</i> , 2008 , 2, 60-2	4.9	16
222	Effect of ezetimibe/simvastatin versus atorvastatin or rosuvastatin on modifying lipid profiles in patients with diabetes, metabolic syndrome, or neither: Results of two subgroup analyses. <i>Journal of Clinical Lipidology</i> , 2008 , 2, 91-105	4.9	17
221	Comparison of the efficacy and safety of a combination tablet of niacin extended-release and simvastatin with simvastatin 80 mg monotherapy: the SEACOAST II (high-dose) study. <i>Journal of Clinical Lipidology</i> , 2008 , 2, 79-90	4.9	34
220	Ezetimibe/simvastatin compared with atorvastatin or rosuvastatin in lowering to specified levels both LDL-C and each of five other emerging risk factors for coronary heart disease: Non-HDL-cholesterol, TC/HDL-C, apolipoprotein B, apo-B/apo-A-I, or C-reactive protein. <i>Journal of Clinical Lipidology</i> , 2008 , 2, 436-46	4.9	12

219	Preoperative statin therapy is not associated with a decrease in the incidence of postoperative atrial fibrillation in patients undergoing cardiac surgery. <i>American Heart Journal</i> , 2008 , 155, 541-6	4.9	61
218	Nine-year trends in achievement of risk factor goals in the US and European outpatients with cardiovascular disease. <i>American Heart Journal</i> , 2008 , 156, 719-27	4.9	75
217	Relationship of alcohol consumption and type of alcoholic beverage consumed with plasma lipid levels: differences between Whites and African Americans of the ARIC study. <i>Annals of Epidemiology</i> , 2008 , 18, 101-7	6.4	55
216	Increased risk of incident stroke associated with the cyclooxygenase 2 (COX-2) G-765C polymorphism in African-Americans: the Atherosclerosis Risk in Communities Study. <i>Atherosclerosis</i> , 2008 , 196, 926-30	3.1	46
215	Low-density lipoprotein and high-density lipoprotein cholesterol levels in relation to genetic polymorphisms and menopausal status: the Atherosclerosis Risk in Communities (ARIC) Study. <i>Atherosclerosis</i> , 2008 , 200, 322-8	3.1	14
214	Extended-release niacin/laropiprant: reducing niacin-induced flushing to better realize the benefit of niacin in improving cardiovascular risk factors. <i>Cardiology Clinics</i> , 2008 , 26, 547-60	2.5	26
213	Developmental control of integrin expression regulates Th2 effector homing. <i>Journal of Immunology</i> , 2008 , 180, 4656-67	5.3	17
212	Effect of rosuvastatin therapy on coronary artery stenoses assessed by quantitative coronary angiography: a study to evaluate the effect of rosuvastatin on intravascular ultrasound-derived coronary atheroma burden. <i>Circulation</i> , 2008 , 117, 2458-66	16.7	148
211	Association of lactate with blood pressure before and after rapid weight loss. <i>American Journal of Hypertension</i> , 2008 , 21, 1337-42	2.3	24
210	APOE/C1/C4/C2 hepatic control region polymorphism influences plasma apoE and LDL cholesterol levels. <i>Human Molecular Genetics</i> , 2008 , 17, 2039-46	5.6	19
209	Del-1, an endogenous leukocyte-endothelial adhesion inhibitor, limits inflammatory cell recruitment. <i>Science</i> , 2008 , 322, 1101-4	33.3	218
208	Association of the complement factor H Y402H polymorphism with cardiovascular disease is dependent upon hypertension status: The ARIC study. <i>American Journal of Hypertension</i> , 2008 , 21, 533-8 ^{2.3}	2.3	25
207	Regulation of LFA-1-dependent inflammatory cell recruitment by Cbl-b and 14-3-3 proteins. <i>Blood</i> , 2008 , 111, 3607-14	2.2	46
206	Expression, activation, and function of integrin alphaMbeta2 (Mac-1) on neutrophil-derived microparticles. <i>Blood</i> , 2008 , 112, 2327-35	2.2	158
205	Peroxisome proliferator-activated receptor [alpha] genetic variation interacts with n-6 and long-chain n-3 fatty acid intake to affect total cholesterol and LDL-cholesterol concentrations in the Atherosclerosis Risk in Communities Study. <i>American Journal of Clinical Nutrition</i> , 2008 , 87, 1926-31	7	43
204	Prevalence of metabolic syndrome and associated risk factors in Asian Indians. <i>Journal of Immigrant and Minority Health</i> , 2008 , 10, 313-23	2.2	27
203	Endothelial domes encapsulate adherent neutrophils and minimize increases in vascular permeability in paracellular and transcellular emigration. <i>PLoS ONE</i> , 2008 , 3, e1649	3.7	85
202	Matrix metalloproteinase-1 and tissue inhibitors do not predict incident coronary artery disease in the atherosclerosis risk in communities (ARIC) study. <i>Texas Heart Institute Journal</i> , 2008 , 35, 388-94	0.8	6

201	The α 2 integrin CD11c is a potent costimulator of CD8 T cell responses. <i>FASEB Journal</i> , 2008 , 22, 855-10	0.9	
200	T-cell accumulation and regulated on activation, normal T cell expressed and secreted upregulation in adipose tissue in obesity. <i>Circulation</i> , 2007 , 115, 1029-38	16.7	507
199	A novel pathway of HMGB1-mediated inflammatory cell recruitment that requires Mac-1-integrin. <i>EMBO Journal</i> , 2007 , 26, 1129-39	13	293
198	Efficacy and safety of rosuvastatin 40 mg alone or in combination with ezetimibe in patients at high risk of cardiovascular disease (results from the EXPLORER study). <i>American Journal of Cardiology</i> , 2007 , 99, 673-80	3	138
197	Biological surrogates for enhancing cardiovascular risk prediction in type 2 diabetes mellitus. <i>American Journal of Cardiology</i> , 2007 , 99, 80B-88B	3	41
196	Comparison of effects of ezetimibe/simvastatin versus simvastatin versus atorvastatin in reducing C-reactive protein and low-density lipoprotein cholesterol levels. <i>American Journal of Cardiology</i> , 2007 , 99, 1706-1713	3	54
195	Long-term efficacy and safety of rosuvastatin 40 mg in patients with severe hypercholesterolemia. <i>American Journal of Cardiology</i> , 2007 , 100, 1387-96	3	21
194	Treatment of dyslipidemia to reduce cardiovascular risk in patients with multiple risk factors. <i>Clinical Cornerstone</i> , 2007 , 8 Suppl 6, S6-13		14
193	Role of biomarkers in developing new therapies for vascular disease. <i>World Journal of Surgery</i> , 2007 , 31, 676-81	3.3	11
192	Peripheral arterial occlusive disease: magnetic resonance imaging and the role of aggressive medical management. <i>World Journal of Surgery</i> , 2007 , 31, 695-704	3.3	19
191	Lipoprotein-associated phospholipase A2: Risk marker or target of therapy?. <i>Current Cardiovascular Risk Reports</i> , 2007 , 1, 66-71	0.9	
190	Cardiometabolic risk in impaired fasting glucose and impaired glucose tolerance: the Atherosclerosis Risk in Communities Study. <i>Diabetes Care</i> , 2007 , 30, 325-31	14.6	71
189	A prospective study of plasma ferritin level and incident diabetes: the Atherosclerosis Risk in Communities (ARIC) Study. <i>American Journal of Epidemiology</i> , 2007 , 165, 1047-54	3.8	97
188	An annual, prospective, international study of outpatients with cardiovascular disease or risk factors: design and methods of the CardioMonitor registry. <i>Critical Pathways in Cardiology</i> , 2007 , 6, 72-5	1.3	1
187	Increasing prevalence of obesity and clustered cardiometabolic risk: can treatment of the underlying cause reverse the trends?. <i>Critical Pathways in Cardiology</i> , 2007 , 6, 41-5	1.3	5
186	Efficacy and tolerability of adding prescription omega-3 fatty acids 4 g/d to simvastatin 40 mg/d in hypertriglyceridemic patients: an 8-week, randomized, double-blind, placebo-controlled study. <i>Clinical Therapeutics</i> , 2007 , 29, 1354-67	3.5	327
185	L5, the most electronegative subfraction of plasma LDL, induces endothelial vascular cell adhesion molecule 1 and CXC chemokines, which mediate mononuclear leukocyte adhesion. <i>Atherosclerosis</i> , 2007 , 192, 56-66	3.1	27
184	Pro-apoptotic low-density lipoprotein subfractions in type II diabetes. <i>Atherosclerosis</i> , 2007 , 193, 283-91	3.1	29

183	Associations between HDL-cholesterol and polymorphisms in hepatic lipase and lipoprotein lipase genes are modified by dietary fat intake in African American and White adults. <i>Atherosclerosis</i> , 2007 , 194, e131-40	3.1	52
182	Cardiac Rehabilitation: Statins and the Rationale for Implementation of Lipid-Lowering Therapy 2007 , 141-156		
181	Lipoprotein-associated phospholipase A2: pathogenic mechanisms and clinical utility for predicting cardiovascular events. <i>Current Atherosclerosis Reports</i> , 2006 , 8, 374-81	6	13
180	Application of recent definitions of the metabolic syndrome to survey data from the National Cholesterol Education Program Evaluation Project Utilizing Novel E-Technology (NEPTUNE II). <i>Journal of the Cardiometabolic Syndrome</i> , 2006 , 1, 295-300		2
179	Combination therapy with statins and omega-3 fatty acids. <i>American Journal of Cardiology</i> , 2006 , 98, 34i-38i	3	65
178	Point: high-sensitivity C-reactive protein and cardiac C-reactive protein assays: is there a need to differentiate?. <i>Clinical Chemistry</i> , 2006 , 52, 1254-6	5.5	8
177	Eotaxin and obesity. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2006 , 91, 256-61	5.6	91
176	Apolipoprotein E polymorphisms predict low density lipoprotein cholesterol levels and carotid artery wall thickness but not incident coronary heart disease in 12,491 ARIC study participants. <i>American Journal of Epidemiology</i> , 2006 , 164, 342-8	3.8	101
175	Adiposopathy: why do adiposity and obesity cause metabolic disease?. <i>Future Lipidology</i> , 2006 , 1, 389-420		48
174	The LFA-1 adhesion molecule is required for protective immunity during pulmonary Mycobacterium tuberculosis infection. <i>Journal of Immunology</i> , 2006 , 176, 4914-22	5.3	43
173	An assessment of incremental coronary risk prediction using C-reactive protein and other novel risk markers: the atherosclerosis risk in communities study. <i>Archives of Internal Medicine</i> , 2006 , 166, 1368-73		265
172	Effect of very high-intensity statin therapy on regression of coronary atherosclerosis: the ASTEROID trial. <i>JAMA - Journal of the American Medical Association</i> , 2006 , 295, 1556-65	27.4	1375
171	Lipid-altering efficacy of the ezetimibe/simvastatin single tablet versus rosuvastatin in hypercholesterolemic patients. <i>Current Medical Research and Opinion</i> , 2006 , 22, 2041-53	2.5	91
170	Intraluminal crawling of neutrophils to emigration sites: a molecularly distinct process from adhesion in the recruitment cascade. <i>Journal of Experimental Medicine</i> , 2006 , 203, 2569-75	16.6	512
169	P-selectin Thr715Pro polymorphism predicts P-selectin levels but not risk of incident coronary heart disease or ischemic stroke in a cohort of 14595 participants: the Atherosclerosis Risk in Communities Study. <i>Atherosclerosis</i> , 2006 , 186, 74-9	3.1	42
168	Effects of diet-induced obesity on inflammation and remodeling after myocardial infarction. <i>American Journal of Physiology - Heart and Circulatory Physiology</i> , 2006 , 291, H2504-14	5.2	86
167	Achieving LDL cholesterol, non-HDL cholesterol, and apolipoprotein B target levels in high-risk patients: Measuring Effective Reductions in Cholesterol Using Rosuvastatin therapy (MERCURY) II. <i>American Heart Journal</i> , 2006 , 151, 975.e1-9	4.9	69
166	Heart positive: design of a randomized controlled clinical trial of intensive lifestyle intervention, niacin and fenofibrate for HIV lipodystrophy/dyslipidemia. <i>Contemporary Clinical Trials</i> , 2006 , 27, 518-30	2.3	18

165	Effectiveness and tolerability of adding ezetimibe to niacin-based regimens for treatment of primary hyperlipidemia. <i>Endocrine Practice</i> , 2006 , 12, 159-64	3.2	16
164	Intraluminal crawling of neutrophils to emigration sites: a molecularly distinct process from adhesion in the recruitment cascade. <i>Journal of Cell Biology</i> , 2006 , 175, i13-i13	7.3	
163	Lipids and CVD management: towards a global consensus. <i>European Heart Journal</i> , 2005 , 26, 2224-31	9.5	66
162	Plasma MCP-1 level and risk for peripheral arterial disease and incident coronary heart disease: Atherosclerosis Risk in Communities study. <i>Atherosclerosis</i> , 2005 , 183, 301-7	3.1	117
161	Markers of inflammation and their clinical significance. <i>Atherosclerosis Supplements</i> , 2005 , 6, 21-9	1.7	108
160	Conditional risk factors for atherosclerosis. <i>Mayo Clinic Proceedings</i> , 2005 , 80, 219-30	6.4	71
159	Extra domain A and type III connecting segment of fibronectin in assembly and cleavage. <i>Biochemical and Biophysical Research Communications</i> , 2005 , 338, 1640-7	3.4	15
158	Dose-comparison study of the combination of ezetimibe and simvastatin (Vytorin) versus atorvastatin in patients with hypercholesterolemia: the Vytorin Versus Atorvastatin (VYVA) study. <i>American Heart Journal</i> , 2005 , 149, 464-73	4.9	205
157	A common PCSK9 haplotype, encompassing the E670G coding single nucleotide polymorphism, is a novel genetic marker for plasma low-density lipoprotein cholesterol levels and severity of coronary atherosclerosis. <i>Journal of the American College of Cardiology</i> , 2005 , 45, 1611-9	15.1	122
156	Apolipoprotein E genotype and incident ischemic stroke: the Atherosclerosis Risk in Communities Study. <i>Stroke</i> , 2005 , 36, 2484-6	6.7	10
155	Statin use and risks of death or fatal rejection in the Heart Transplant Lipid Registry. <i>American Journal of Cardiology</i> , 2005 , 95, 367-72	3	36
154	Results of the National Cholesterol Education (NCEP) Program Evaluation Project Utilizing Novel E-Technology (NEPTUNE) II survey and implications for treatment under the recent NCEP Writing Group recommendations. <i>American Journal of Cardiology</i> , 2005 , 96, 556-63	3	233
153	Rationale for targeting multiple lipid pathways for optimal cardiovascular risk reduction. <i>American Journal of Cardiology</i> , 2005 , 96, 14K-19K; discussion 34K-35K	3	13
152	Cardiometabolic risk assessment: an approach to the prevention of cardiovascular disease and diabetes mellitus. <i>Clinical Cornerstone</i> , 2005 , 7, 7-16		23
151	Utility of statin therapy using high-sensitivity C-reactive protein as an indicator of coronary heart disease risk. <i>Current Atherosclerosis Reports</i> , 2005 , 7, 22-8	6	7
150	Comparison of the instructional efficacy of Internet-based CME with live interactive CME workshops: a randomized controlled trial. <i>JAMA - Journal of the American Medical Association</i> , 2005 , 294, 1043-51	27.4	272
149	A comparative study with rosuvastatin in subjects with metabolic syndrome: results of the COMETS study. <i>European Heart Journal</i> , 2005 , 26, 2664-72	9.5	89
148	Identifying individuals at high risk for diabetes: The Atherosclerosis Risk in Communities study. <i>Diabetes Care</i> , 2005 , 28, 2013-8	14.6	339

147	PLAC test for identification of individuals at increased risk for coronary heart disease. <i>Expert Review of Molecular Diagnostics</i> , 2005 , 5, 9-14	3.8	21
146	Manifestations of inflammatory arthritis are critically dependent on LFA-1. <i>Journal of Immunology</i> , 2005 , 174, 3668-75	5.3	71
145	The metabolic syndrome and 11-year risk of incident cardiovascular disease in the atherosclerosis risk in communities study. <i>Diabetes Care</i> , 2005 , 28, 385-90	14.6	851
144	Multiplexed analysis of biomarkers related to obesity and the metabolic syndrome in human plasma, using the Luminex-100 system. <i>Clinical Chemistry</i> , 2005 , 51, 1102-9	5.5	145
143	Fat, fit, and leading the charge: the evolution of measuring high-density lipoprotein subpopulations. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2005 , 25, 2013-5	9.4	3
142	Lipoprotein-associated phospholipase A2, high-sensitivity C-reactive protein, and risk for incident ischemic stroke in middle-aged men and women in the Atherosclerosis Risk in Communities (ARIC) study. <i>Archives of Internal Medicine</i> , 2005 , 165, 2479-84		219
141	Cholesterol, lipids, and statins. <i>Texas Heart Institute Journal</i> , 2005 , 32, 378-9	0.8	6
140	LDL-C goal attainment with ezetimibe plus simvastatin coadministration vs atorvastatin or simvastatin monotherapy in patients at high risk of CHD. <i>MedGenMed: Medscape General Medicine</i> , 2005 , 7, 3		3
139	Relationship between low-density lipoprotein subclasses and asymptomatic atherosclerosis in subjects from the Atherosclerosis Risk in Communities (ARIC) Study. <i>Biomarkers</i> , 2004 , 9, 190-202	2.6	15
138	Reduction of cardiovascular events by simvastatin in nondiabetic coronary heart disease patients with and without the metabolic syndrome: subgroup analyses of the Scandinavian Simvastatin Survival Study (4S). <i>Diabetes Care</i> , 2004 , 27, 1735-40	14.6	129
137	Cardiology patient page. Measurement of cholesterol: a patient perspective. <i>Circulation</i> , 2004 , 110, e296-7	6.7	21
136	Adiponectin, inflammation, and the expression of the metabolic syndrome in obese individuals: the impact of rapid weight loss through caloric restriction. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2004 , 89, 2697-703	5.6	218
135	Adiponectin and the development of type 2 diabetes: the atherosclerosis risk in communities study. <i>Diabetes</i> , 2004 , 53, 2473-8	0.9	280
134	Deficiency of CD11b or CD11d results in reduced staphylococcal enterotoxin-induced T cell response and T cell phenotypic changes. <i>Journal of Immunology</i> , 2004 , 173, 297-306	5.3	67
133	Fasting plasma free fatty acids and risk of type 2 diabetes: the atherosclerosis risk in communities study. <i>Diabetes Care</i> , 2004 , 27, 77-82	14.6	113
132	The virulence function of <i>Streptococcus pneumoniae</i> surface protein A involves inhibition of complement activation and impairment of complement receptor-mediated protection. <i>Journal of Immunology</i> , 2004 , 173, 7506-12	5.3	95
131	Lipoprotein-associated phospholipase A2, high-sensitivity C-reactive protein, and risk for incident coronary heart disease in middle-aged men and women in the Atherosclerosis Risk in Communities (ARIC) study. <i>Circulation</i> , 2004 , 109, 837-42	16.7	525
130	Efficacy and safety of ezetimibe co-administered with simvastatin compared with atorvastatin in adults with hypercholesterolemia. <i>American Journal of Cardiology</i> , 2004 , 93, 1487-94	3	159

129	Effectiveness and tolerability of ezetimibe add-on therapy to a bile acid resin-based regimen for hypercholesterolemia. <i>American Journal of Cardiology</i> , 2004 , 94, 795-7	3	47
128	Prevalence of coronary heart disease and carotid arterial thickening in patients with the metabolic syndrome (The ARIC Study). <i>American Journal of Cardiology</i> , 2004 , 94, 1249-54	3	139
127	Fluvastatin reduces cardiac mortality in patients with coronary heart disease. <i>Cardiovascular Drugs and Therapy</i> , 2004 , 18, 67-75	3.9	7
126	Cardiovascular implications of HIV-associated dyslipidemic lipodystrophy. <i>Current Atherosclerosis Reports</i> , 2004 , 6, 173-9	6	16
125	ASCOT-LLA and the primary prevention of coronary artery disease in hypertensive patients. <i>Current Atherosclerosis Reports</i> , 2004 , 6, 353-8	6	1
124	Endothelial lipase and cholesterol metabolism. <i>Current Atherosclerosis Reports</i> , 2004 , 6, 126-30	6	9
123	Role of selective cholesterol absorption inhibition in the management of dyslipidemia. <i>Current Atherosclerosis Reports</i> , 2004 , 6, 52-9	6	7
122	Tracking regression and progression of atherosclerosis in human carotid arteries using high-resolution magnetic resonance imaging. <i>Magnetic Resonance Imaging</i> , 2004 , 22, 1249-58	3.3	51
121	Follow-up lipid tests and physician visits are associated with improved adherence to statin therapy. <i>Pharmacoeconomics</i> , 2004 , 22 Suppl 3, 13-23	4.4	88
120	Management of metabolic syndrome: statins. <i>Endocrinology and Metabolism Clinics of North America</i> , 2004 , 33, 509-23, vi	5.5	7
119	Fluvastatin: clinical and safety profile. <i>Drugs</i> , 2004 , 64, 1305-23	12.1	19
118	Efficacy and safety of rosuvastatin alone and in combination with cholestyramine in patients with severe hypercholesterolemia: a randomized, open-label, multicenter trial. <i>Clinical Therapeutics</i> , 2004 , 26, 1855-64	3.5	25
117	Loss of LFA-1, but not Mac-1, protects MRL/MpJ-Fas(lpr) mice from autoimmune disease. <i>American Journal of Pathology</i> , 2004 , 165, 609-16	5.8	63
116	Achieving greater reductions in cardiovascular risk: lessons from statin therapy on risk measures and risk reduction. <i>American Heart Journal</i> , 2004 , 148, S3-8	4.9	10
115	Effects of PPARalpha, gamma and delta haplotypes on plasma levels of lipids, severity and progression of coronary atherosclerosis and response to statin therapy in the lipoprotein coronary atherosclerosis study. <i>Pharmacogenetics and Genomics</i> , 2004 , 14, 61-71		45
114	Integrin engagement regulates monocyte differentiation through the forkhead transcription factor Foxp1. <i>Journal of Clinical Investigation</i> , 2004 , 114, 408-418	15.9	73
113	Integrin engagement regulates monocyte differentiation through the forkhead transcription factor Foxp1. <i>Journal of Clinical Investigation</i> , 2004 , 114, 408-18	15.9	49
112	Gender-Dependent Up-Regulation of the VWF-Cleaving metalloprotease ADAMTS-13 in Mice with Obesity and Hypercholesterolemia.. <i>Blood</i> , 2004 , 104, 3500-3500	2.2	

111	Strategies for optimizing lipid management. <i>Postgraduate Medicine</i> , 2004 , 116, 13-20	3.7	
110	Host resistance of CD18 knockout mice against systemic infection with <i>Listeria monocytogenes</i> . <i>Infection and Immunity</i> , 2003 , 71, 5986-93	3.7	17
109	Mac-1, but not LFA-1, uses intercellular adhesion molecule-1 to mediate slow leukocyte rolling in TNF-alpha-induced inflammation. <i>Journal of Immunology</i> , 2003 , 171, 6105-11	5.3	103
108	Low-grade systemic inflammation and the development of type 2 diabetes: the atherosclerosis risk in communities study. <i>Diabetes</i> , 2003 , 52, 1799-805	0.9	754
107	Plasma lipid profile and incident ischemic stroke: the Atherosclerosis Risk in Communities (ARIC) study. <i>Stroke</i> , 2003 , 34, 623-31	6.7	242
106	Role of non-high-density lipoprotein cholesterol in prevention of cardiovascular disease: updated evidence from clinical trials. <i>Current Opinion in Cardiology</i> , 2003 , 18, 503-9	2.1	17
105	Roles of neutrophil beta 2 integrins in kinetics of bacteremia, extravasation, and tick acquisition of <i>Anaplasma phagocytophila</i> in mice. <i>Blood</i> , 2003 , 101, 3257-64	2.2	19
104	Comparative effects of rosuvastatin and atorvastatin across their dose ranges in patients with hypercholesterolemia and without active arterial disease. <i>American Journal of Cardiology</i> , 2003 , 91, 33-41	3.2	106
103	Efficacy of rosuvastatin 10 mg in patients with the metabolic syndrome. <i>American Journal of Cardiology</i> , 2003 , 91, 25C-27C; discussion 28C	3	34
102	Management of persons with high risk of coronary heart disease but low serum low-density lipoprotein cholesterol. <i>American Journal of Cardiology</i> , 2003 , 91, 1134-6	3	5
101	Current and future aims of lipid-lowering therapy: changing paradigms and lessons from the Heart Protection Study on standards of efficacy and safety. <i>American Journal of Cardiology</i> , 2003 , 92, 3K-9K	3	98
100	B vitamin status and inflammatory markers. <i>Atherosclerosis</i> , 2003 , 169, 169-74	3.1	52
99	Platelet-monocyte complex formation: effect of blocking PSGL-1 alone, and in combination with alphaIIb beta3 and alphaM beta2, in coronary stenting. <i>Thrombosis Research</i> , 2003 , 111, 171-7	8.2	39
98	Role of lipid and lipoprotein profiles in risk assessment and therapy. <i>American Heart Journal</i> , 2003 , 146, 227-33	4.9	50
97	Effect on high-density lipoprotein cholesterol of maximum dose simvastatin and atorvastatin in patients with hypercholesterolemia: results of the Comparative HDL Efficacy and Safety Study (CHESS). <i>American Heart Journal</i> , 2003 , 146, 862-9	4.9	59
96	Effect of ezetimibe coadministered with atorvastatin in 628 patients with primary hypercholesterolemia: a prospective, randomized, double-blind trial. <i>Circulation</i> , 2003 , 107, 2409-15	16.7	524
95	Glutathione-S-transferase genotypes, smoking, and their association with markers of inflammation, hemostasis, and endothelial function: the atherosclerosis risk in communities (ARIC) study. <i>Atherosclerosis</i> , 2003 , 171, 265-72	3.1	55
94	Comparative effects of simvastatin and atorvastatin in hypercholesterolemic patients with characteristics of metabolic syndrome. <i>Clinical Therapeutics</i> , 2003 , 25, 1670-86	3.5	40

93	From vulnerable plaque to vulnerable patient: a call for new definitions and risk assessment strategies: Part I. <i>Circulation</i> , 2003 , 108, 1664-72	16.7	1985
92	From vulnerable plaque to vulnerable patient: a call for new definitions and risk assessment strategies: Part II. <i>Circulation</i> , 2003 , 108, 1772-8	16.7	886
91	Risk for myopathy with statin therapy in high-risk patients. <i>Archives of Internal Medicine</i> , 2003 , 163, 553-64		338
90	Interaction between soluble thrombomodulin and intercellular adhesion molecule-1 in predicting risk of coronary heart disease. <i>Circulation</i> , 2003 , 107, 1729-32	16.7	45
89	Long-term, randomized clinical trial of two diets in the metabolic syndrome and type 2 diabetes. <i>Diabetes Care</i> , 2003 , 26, 2481-2	14.6	27
88	Low-density lipoprotein in hypercholesterolemic human plasma induces vascular endothelial cell apoptosis by inhibiting fibroblast growth factor 2 transcription. <i>Circulation</i> , 2003 , 107, 2102-8	16.7	129
87	Endothelial lipase is a major genetic determinant for high-density lipoprotein concentration, structure, and metabolism. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2003 , 100, 2748-53	11.5	202
86	Detection of undiagnosed diabetes and other hyperglycemia states: the Atherosclerosis Risk in Communities Study. <i>Diabetes Care</i> , 2003 , 26, 1338-43	14.6	33
85	Unanswered questions about the use of statins 2003 , 228-240		
84	Combination therapy for combined dyslipidemia. <i>American Journal of Cardiology</i> , 2002 , 90, 21K-29K	3	44
83	LPL polymorphism predicts stroke risk in men. <i>Genetic Epidemiology</i> , 2002 , 22, 233-42	2.6	38
82	Statins and inflammatory markers. <i>Current Atherosclerosis Reports</i> , 2002 , 4, 42-7	6	17
81	Effects of SREBF-1a and SCAP polymorphisms on plasma levels of lipids, severity, progression and regression of coronary atherosclerosis and response to therapy with fluvastatin. <i>Journal of Molecular Medicine</i> , 2002 , 80, 737-44	5.5	39
80	Kinetics of CD11b/CD18 up-regulation during infection with the agent of human granulocytic ehrlichiosis in mice. <i>Laboratory Investigation</i> , 2002 , 82, 303-11	5.9	25
79	Effects of sirolimus on plasma lipids, lipoprotein levels, and fatty acid metabolism in renal transplant patients. <i>Journal of Lipid Research</i> , 2002 , 43, 1170-1180	6.3	213
78	Role of alpha4 integrin and VCAM-1 in CD18-independent neutrophil migration across mouse cardiac endothelium. <i>Circulation Research</i> , 2002 , 90, 562-9	15.7	93
77	Control of leukocyte rolling velocity in TNF-alpha-induced inflammation by LFA-1 and Mac-1. <i>Blood</i> , 2002 , 99, 336-41	2.2	166
76	Soluble adhesion molecules and coronary heart disease. <i>Lancet, The</i> , 2002 , 359, 525; author reply 526-7	40	3

75	Cardiovascular risk factors associated with immunosuppression in renal transplantation. <i>Transplantation Reviews</i> , 2002 , 16, 1-21	3.3	16
74	Use of Denaturing HPLC to Provide Efficient Detection of Mutations Causing Familial Hypercholesterolemia. <i>Clinical Chemistry</i> , 2002 , 48, 1913-1918	5.5	24
73	Effects of sirolimus on plasma lipids, lipoprotein levels, and fatty acid metabolism in renal transplant patients. <i>Journal of Lipid Research</i> , 2002 , 43, 1170-80	6.3	88
72	Use of denaturing HPLC to provide efficient detection of mutations causing familial hypercholesterolemia. <i>Clinical Chemistry</i> , 2002 , 48, 1913-8	5.5	5
71	Newer risk markers and surrogate endpoints in atherosclerosis management. <i>Clinical Cardiology</i> , 2001 , 24, III13-7	3.3	4
70	Treating mixed dyslipidemias: why and how. <i>Clinical Cardiology</i> , 2001 , 24, II-6-9	3.3	9
69	Correlation of non-high-density lipoprotein cholesterol with apolipoprotein B: effect of 5 hydroxymethylglutaryl coenzyme A reductase inhibitors on non-high-density lipoprotein cholesterol levels. <i>American Journal of Cardiology</i> , 2001 , 88, 265-9	3	148
68	The differential roles of LFA-1 and Mac-1 in host defense against systemic infection with <i>Streptococcus pneumoniae</i> . <i>Journal of Immunology</i> , 2001 , 166, 7362-9	5.3	73
67	Novel polymorphisms in promoter region of atp binding cassette transporter gene and plasma lipids, severity, progression, and regression of coronary atherosclerosis and response to therapy. <i>Circulation Research</i> , 2001 , 88, 969-73	15.7	96
66	Influence of low high-density lipoprotein cholesterol and elevated triglyceride on coronary heart disease events and response to simvastatin therapy in 4S. <i>Circulation</i> , 2001 , 104, 3046-51	16.7	335
65	A prospective study of paraoxonase gene Q/R192 polymorphism and severity, progression and regression of coronary atherosclerosis, plasma lipid levels, clinical events and response to fluvastatin. <i>Atherosclerosis</i> , 2001 , 154, 633-40	3.1	50
64	The evolving role of high-density lipoprotein in reducing cardiovascular risk. <i>Preventive Cardiology</i> , 2001 , 4, 65-72		2
63	Achieving and maintaining National Cholesterol Education Program low-density lipoprotein cholesterol goals with five statins. <i>American Journal of Medicine</i> , 2001 , 111, 185-91	2.4	150
62	Efficacy and tolerability of fluvastatin extended-release delivery system: a pooled analysis. <i>Clinical Therapeutics</i> , 2001 , 23, 177-92	3.5	64
61	Effect of sirolimus on the metabolism of apoB100- containing lipoproteins in renal transplant patients. <i>Transplantation</i> , 2001 , 72, 1244-50	1.8	104
60	Mechanism of chronic obstructive uropathy: increased expression of apoptosis-promoting molecules. <i>Kidney International</i> , 2000 , 58, 1481-91	9.9	59
59	A symposium: lipid management summit on improving practice outcome. Introduction. <i>American Journal of Cardiology</i> , 2000 , 85, 1A-2A	3	1
58	Strategies for implementing lipid-lowering therapy: pharmacy-based approach. <i>American Journal of Cardiology</i> , 2000 , 85, 30A-35A	3	21

57	Efficacy and safety of an extended-release formulation of fluvastatin for once-daily treatment of primary hypercholesterolemia. <i>American Journal of Cardiology</i> , 2000 , 86, 759-63	3	21
56	Development and assessment of antiatherosclerotic therapies beyond low-density lipoprotein cholesterol and blood pressure. <i>Current Atherosclerosis Reports</i> , 2000 , 2, 281-3	6	
55	A prospective study of genetic markers of susceptibility to infection and inflammation, and the severity, progression, and regression of coronary atherosclerosis and its response to therapy. <i>Journal of Molecular Medicine</i> , 2000 , 78, 562-8	5.5	26
54	Hydrogen peroxide induces LFA-1-dependent neutrophil adherence to cardiac myocytes. <i>American Journal of Physiology - Heart and Circulatory Physiology</i> , 2000 , 278, H835-42	5.2	13
53	A variant of p22(phox), involved in generation of reactive oxygen species in the vessel wall, is associated with progression of coronary atherosclerosis. <i>Circulation Research</i> , 2000 , 86, 391-5	15.7	118
52	Platelet glycoprotein Iba1 is a counterreceptor for the leukocyte integrin Mac-1 (CD11b/CD18). <i>Journal of Experimental Medicine</i> , 2000 , 192, 193-204	16.6	476
51	Hyperlipidemia: diagnostic and therapeutic perspectives. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2000 , 85, 2089-112	5.6	37
50	Impact of evidence-based "clinical judgment" on the number of American adults requiring lipid-lowering therapy based on updated NHANES III data. National Health and Nutrition Examination Survey. <i>Archives of Internal Medicine</i> , 2000 , 160, 1361-9		60
49	IL-10 is induced in the reperfused myocardium and may modulate the reaction to injury. <i>Journal of Immunology</i> , 2000 , 165, 2798-808	5.3	230
48	Interactions between angiotensin-I converting enzyme insertion/deletion polymorphism and response of plasma lipids and coronary atherosclerosis to treatment with fluvastatin: the lipoprotein and coronary atherosclerosis study. <i>Journal of the American College of Cardiology</i> , 2000 , 35, 22-25	15.1	71
47	Apolipoprotein E genotypes and response of plasma lipids and progression-regression of coronary atherosclerosis to lipid-lowering drug therapy. <i>Journal of the American College of Cardiology</i> , 2000 , 36, 1572-8	15.1	83
46	Decreased neointimal formation in Mac-1(-/-) mice reveals a role for inflammation in vascular repair after angioplasty. <i>Journal of Clinical Investigation</i> , 2000 , 105, 293-300	15.9	192
45	Leukocyte CD11b expression is not essential for the development of atherosclerosis in mice. <i>Journal of Lipid Research</i> , 2000 , 41, 1060-1066	6.3	24
44	Myocardial infarction and remodeling in mice: effect of reperfusion. <i>American Journal of Physiology - Heart and Circulatory Physiology</i> , 1999 , 277, H660-8	5.2	65
43	Effect of moderate alcohol consumption on hypertriglyceridemia: a study in the fasting state. <i>Archives of Internal Medicine</i> , 1999 , 159, 981-7		47
42	Influence of low HDL on progression of coronary artery disease and response to fluvastatin therapy. <i>Circulation</i> , 1999 , 99, 736-43	16.7	173
41	Adhesion molecules in cardiovascular disease. <i>Expert Opinion on Therapeutic Targets</i> , 1999 , 3, 263-277		3
40	Reducing atherothrombotic events in high-risk patients: recent data on therapy with statins and fatty acids. <i>Current Atherosclerosis Reports</i> , 1999 , 1, 6-8	6	3

39	Inflammation and lipid-lowering treatment. <i>Current Cardiology Reports</i> , 1999 , 1, 251-5	4.2	1
38	Correlation of serum triglyceride and its reduction by omega-3 fatty acids with lipid transfer activity and the neutral lipid compositions of high-density and low-density lipoproteins. <i>Atherosclerosis</i> , 1999 , 143, 285-97	3.1	146
37	Lipoprotein lipase gene mutations, plasma lipid levels, progression/regression of coronary atherosclerosis, response to therapy, and future clinical events. Lipoproteins and Coronary Atherosclerosis Study. <i>Atherosclerosis</i> , 1999 , 144, 435-42	3.1	32
36	Clinical trial endpoints: angiograms, events, and plaque instability. <i>American Journal of Cardiology</i> , 1998 , 82, 5M-11M	3	48
35	Low-density lipoproteins and risk for coronary artery disease. <i>American Journal of Cardiology</i> , 1998 , 82, 3Q-12Q	3	270
34	Cytokines and the microcirculation in ischemia and reperfusion. <i>Journal of Molecular and Cellular Cardiology</i> , 1998 , 30, 2567-76	5.8	150
33	Current thinking in lipid lowering. <i>American Journal of Medicine</i> , 1998 , 104, 33S-41S	2.4	17
32	Soluble cell adhesion molecules in hypertriglyceridemia and potential significance on monocyte adhesion. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 1998 , 18, 723-31	9.4	177
31	Stem cell factor induction is associated with mast cell accumulation after canine myocardial ischemia and reperfusion. <i>Circulation</i> , 1998 , 98, 687-98	16.7	153
30	Maximizing the cost-effectiveness of lipid-lowering therapy. <i>Archives of Internal Medicine</i> , 1998 , 158, 1977-89		54
29	Pathophysiology of Atherosclerosis. <i>Developments in Cardiovascular Medicine</i> , 1998 , 3-58		
28	Dyslipidemia, Diabetes, and Cell Adhesion Molecules. <i>Medical Science Symposia Series</i> , 1998 , 191-198		
27	Effects of lipid lowering therapy on progression of coronary and carotid artery disease. <i>Current Opinion in Lipidology</i> , 1997 , 8, 354-61	4.4	39
26	Pathophysiology and treatment of lipid perturbation after cardiac transplantation. <i>Current Opinion in Cardiology</i> , 1997 , 12, 153-60	2.1	17
25	Molecular markers for atherosclerosis. <i>European Journal of Cardiovascular Prevention and Rehabilitation</i> , 1997 , 4, 353-356		6
24	Phagocytes in ischemia injury. <i>Annals of the New York Academy of Sciences</i> , 1997 , 832, 243-65	6.5	9
23	Effects of fluvastatin on coronary atherosclerosis in patients with mild to moderate cholesterol elevations (Lipoprotein and Coronary Atherosclerosis Study [LCAS]). <i>American Journal of Cardiology</i> , 1997 , 80, 278-86	3	273
22	Induction of monocyte chemoattractant protein-1 in the small veins of the ischemic and reperfused canine myocardium. <i>Circulation</i> , 1997 , 95, 693-700	16.7	129

21	Circulating adhesion molecules VCAM-1, ICAM-1, and E-selectin in carotid atherosclerosis and incident coronary heart disease cases: the Atherosclerosis Risk In Communities (ARIC) study. <i>Circulation</i> , 1997 , 96, 4219-25	16.7	919
20	Treatment of hyperlipidemia after heart transplantation and rationale for the Heart Transplant Lipid Registry. <i>American Journal of Cardiology</i> , 1996 , 78, 532-5	3	16
19	Levels of soluble cell adhesion molecules in patients with dyslipidemia. <i>Circulation</i> , 1996 , 93, 1334-8	16.7	206
18	Association of neutrophils with platelet aggregates in unstable angina. Should we alter therapy?. <i>Circulation</i> , 1996 , 94, 1206-8	16.7	18
17	A Metabolic Model for the Hypolipidemic and Antiatherogenic Effects of N-3 Fatty Acids: Effect of Omacor on Plasma Lipids. <i>Medical Science Symposia Series</i> , 1996 , 675-680		1
16	Role of early reperfusion in the induction of adhesion molecules and cytokines in previously ischemic myocardium. <i>Molecular and Cellular Biochemistry</i> , 1995 , 147, 5-12	4.2	49
15	Cloning and comparative sequence analysis of the gene encoding canine intercellular adhesion molecule-1 (ICAM-1). <i>Gene</i> , 1995 , 156, 291-5	3.8	12
14	Cardiac allograft survival in mice deficient in intercellular adhesion molecule-1. <i>Circulation</i> , 1995 , 92, 82-7	16.7	37
13	Baseline characteristics of subjects in the Lipoprotein and Coronary Atherosclerosis Study (LCAS) with fluvastatin. <i>American Journal of Cardiology</i> , 1994 , 73, 42D-49D	3	17
12	Regulation of ICAM-1 and IL-6 in Myocardial Ischemia: Effect of Reperfusion a. <i>Annals of the New York Academy of Sciences</i> , 1994 , 723, 258-270	6.5	41
11	Increases in lung tissue expression of intercellular adhesion molecule-1 are associated with hyperoxic lung injury and inflammation in mice. <i>American Journal of Respiratory Cell and Molecular Biology</i> , 1993 , 9, 393-400	5.7	52
10	Characterization of the murine Icam-1 gene. <i>Genomics</i> , 1992 , 14, 1076-80	4.3	35
9	Hyperlipidemia after heart transplantation: report of a 6-year experience, with treatment recommendations. <i>Journal of the American College of Cardiology</i> , 1992 , 19, 1315-21	15.1	117
8	Insensitivity of noninvasive tests to detect coronary artery vasculopathy after heart transplant. <i>American Journal of Cardiology</i> , 1991 , 67, 243-7	3	167
7	Lipoprotein(a) and apolipoprotein changes after cardiac transplantation. <i>Journal of the American College of Cardiology</i> , 1991 , 18, 926-30	15.1	38
6	Assignment of the gene for intercellular adhesion molecule-1 (Icam-1) to proximal mouse chromosome 9. <i>Genomics</i> , 1991 , 9, 547-50	4.3	21
5	Nucleotide sequence of the cDNA for murine intercellular adhesion molecule-1 (ICAM-1). <i>Nucleic Acids Research</i> , 1989 , 17, 5853	20.1	38
4	Effects of Cyclosporine Therapy on Plasma Lipoprotein Levels. <i>JAMA - Journal of the American Medical Association</i> , 1989 , 262, 53	27.4	154

3	Low-density lipoprotein metabolism in cerebrotendinous xanthomatosis. <i>Metabolism: Clinical and Experimental</i> , 1987 , 36, 270-6	12.7	27
2	Newer Markers for Population Screening: Focus on Lipoprotein-Related Markers	181-203	
1	Rare coding variants in 35 genes associate with circulating lipid levels in a multi-ancestry analysis of 170,000 exomes		2